<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Open Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Open Biol</journal-id>
<journal-id journal-id-type="publisher-id">RSOB</journal-id>
<journal-id journal-id-type="hwp">royopenbio</journal-id>
<journal-title-group>
<journal-title>Open Biology</journal-title>
</journal-title-group>
<issn pub-type="epub">2046-2441</issn>
<publisher>
<publisher-name>The Royal Society</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29445033</article-id>
<article-id pub-id-type="pmc">5830535</article-id>
<article-id pub-id-type="doi">10.1098/rsob.170216</article-id>
<article-id pub-id-type="publisher-id">rsob170216</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>1001</subject>
<subject>197</subject>
<subject>129</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
<subj-group subj-group-type="leader">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Rett syndrome: a neurological disorder with metabolic components</article-title>
<alt-title alt-title-type="short">Neuro-metabolism in Rett syndrome</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kyle</surname>
<given-names>Stephanie M.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
<xref ref-type="author-notes" rid="an2">†</xref>
<xref ref-type="author-notes" rid="an1">‡</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-0880-245X</contrib-id>
<name>
<surname>Vashi</surname>
<given-names>Neeti</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af3">3</xref>
<xref ref-type="author-notes" rid="an1">†</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-3562-2099</contrib-id>
<name>
<surname>Justice</surname>
<given-names>Monica J.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
<xref ref-type="aff" rid="af3">3</xref>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label><institution>Genetics and Genome Biology Program, The Hospital for Sick Children, The Peter Gilgan Centre for Research and Learning</institution>, <addr-line>Toronto, Ontario</addr-line>, <country>Canada</country>
<addr-line>M5G 0A4</addr-line></aff>
<aff id="af2"><label>2</label><institution>Department of Molecular and Human Genetics, Baylor College of Medicine</institution>, <addr-line>Houston, TX 77030</addr-line>, <country>USA</country></aff>
<aff id="af3"><label>3</label><institution>Department of Molecular Genetics, University of Toronto</institution>, <addr-line>Toronto, Ontario</addr-line>, <country>Canada</country>
<addr-line>M5S 1A1</addr-line></aff>
<author-notes>
<corresp id="cor1">e-mail: <email>monica.justice@sickkids.ca</email></corresp>
<fn fn-type="con" id="an2">
<label>†</label>
<p>These authors contributed equally to this study.</p>
</fn>
<fn fn-type="present-address" id="an1">
<label>‡</label>
<p>Present address: Department of Cell Biology, Emory University, Atlanta, GA 30322, USA.</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>14</day>
<month>2</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>8</volume>
<issue>2</issue>
<elocation-id>170216</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>9</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>1</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 The Authors.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>Published by the Royal Society under the terms of the Creative Commons Attribution License <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>, which permits unrestricted use, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="rsob-8-170216.pdf"></self-uri>
<self-uri xlink:href="rsob170216.thumb.gif" xlink:role="icon"></self-uri>
<self-uri content-type="reviewer_comments" xlink:href="rsob170216_review_history.pdf"></self-uri>
<abstract>
<p>Rett syndrome (RTT) is a neurological disorder caused by mutations in the X-linked gene methyl-CpG-binding protein 2 (<italic>MECP2</italic>), a ubiquitously expressed transcriptional regulator. Despite remarkable scientific progress since its discovery, the mechanism by which <italic>MECP2</italic> mutations cause RTT symptoms is largely unknown. Consequently, treatment options for patients are currently limited and centred on symptom relief. Thought to be an entirely neurological disorder, RTT research has focused on the role of <italic>MECP2</italic> in the central nervous system. However, the variety of phenotypes identified in <italic>Mecp2</italic> mutant mouse models and RTT patients implicate important roles for MeCP2 in peripheral systems. Here, we review the history of RTT, highlighting breakthroughs in the field that have led us to present day. We explore the current evidence supporting metabolic dysfunction as a component of RTT, presenting recent studies that have revealed perturbed lipid metabolism in the brain and peripheral tissues of mouse models and patients. Such findings may have an impact on the quality of life of RTT patients as both dietary and drug intervention can alter lipid metabolism. Ultimately, we conclude that a thorough knowledge of MeCP2's varied functional targets in the brain and body will be required to treat this complex syndrome.</p>
</abstract>
<kwd-group>
<kwd>Rett syndrome</kwd>
<kwd>methyl-CpG-binding protein 2</kwd>
<kwd>histone deacetylase</kwd>
<kwd>nuclear corepressor</kwd>
<kwd>metabolism</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Angel Ava Fund</institution>
</institution-wrap>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Rett Syndrome Research Trust</institution>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>February 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1">
<label>1.</label>
<title>Rett syndrome: clinical features and stages</title>
<p>Rett syndrome (RTT, OMIM #312750) was first described by Andreas Rett, an Austrian paediatric neurologist, after observing two female patients with identical hand-wringing stereotypies in his clinic waiting room. Upon examination, he found that both patients had the same history: normal early development, followed by a period of regression and loss of purposeful hand movements. Intrigued, Dr Rett documented other female patients in his clinic with similar symptoms. Believing the symptoms to be consistent with a metabolic disorder, he called it ‘cerebroatrophic hyperammonaemia’ in a 1966 German publication [<xref ref-type="bibr" rid="RSOB170216C1">1</xref>]. However, the disorder did not gain general acceptance among the medical community until its description in English publications 17 years later [<xref ref-type="bibr" rid="RSOB170216C2">2</xref>]. RTT is now well known as a progressive neurological disorder that primarily affects girls, occurring in 1 : 10 000–15 000 live female births [<xref ref-type="bibr" rid="RSOB170216C3">3</xref>].</p>
<p>The clinical diagnosis of RTT is based on a battery of co-existing and well-defined inclusive and exclusive criteria (summarized in [<xref ref-type="bibr" rid="RSOB170216C4">4</xref>–<xref ref-type="bibr" rid="RSOB170216C6">6</xref>]). Following a period of normal neurological and physical development during the first 6–18 months of life, the first features of RTT begin to manifest in early childhood and appear progressively over several stages (<xref ref-type="fig" rid="RSOB170216F1">figure 1</xref>): stagnation (age 6–18 months), rapid regression (age 1–4 years), pseudostationary (age 2–potentially life) and late motor deterioration (age 10–life). Characteristic symptoms of RTT include loss of acquired speech and motor skills, repetitive hand movements, breathing irregularities and seizures. RTT patients may also suffer from sporadic episodes of gastrointestinal problems, hypoplasia, early-onset osteoporosis, bruxism and screaming spells [<xref ref-type="bibr" rid="RSOB170216C4">4</xref>]. Despite these impairments, RTT patients are well integrated into their families and enjoy personal contact [<xref ref-type="bibr" rid="RSOB170216C7">7</xref>]. The development of new augmentative communication technologies has allowed otherwise non-verbal RTT patients to engage with others and express themselves [<xref ref-type="bibr" rid="RSOB170216C8">8</xref>].
<fig id="RSOB170216F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Timeline of stages and symptom onset in RTT patients. Rett syndrome (RTT) is divided into four progressive stages. Patients display seemingly normal early development. Between 6 and 18 months of age, patients experience a period of developmental stagnation (Stage I) and no longer meet their mental, cognitive or motor milestones. Head circumference growth slows and this period lasts for weeks to months. Stage II is defined by rapid developmental regression in which acquired purposeful hand movements and verbal skills are lost. Microcephaly worsens and breathing irregularities and/or seizures arise. Stage III is a pseudo-stationary plateau period in which patients may show mild recovery in cognitive interests, but purposeful hand and body movements remain severely diminished. Stage IV is defined by motor deterioration and may last decades. Many patients are wheelchair and/or gastrostomy-tube dependent. However, not all girls progress to this severe stage.</p></caption><graphic xlink:href="rsob-8-170216-g1"></graphic></fig></p>
<p>Many children diagnosed with RTT have reduced brain volume compared with healthy individuals, consistent with a smaller head circumference [<xref ref-type="bibr" rid="RSOB170216C9">9</xref>,<xref ref-type="bibr" rid="RSOB170216C10">10</xref>]. Reduced brain volume is largely due to small neuronal body size and a denser packing of cells, particularly in layers III and V of the cerebral cortex, thalamus, substantia nigra, basal ganglia, amygdala, cerebellum and hippocampus [<xref ref-type="bibr" rid="RSOB170216C11">11</xref>]. Patients also have reduced dendritic arborization, indicative of a delay in neuronal maturation [<xref ref-type="bibr" rid="RSOB170216C12">12</xref>]. Furthermore, hypopigmentation of the substantia nigra suggests a dysfunction of dopaminergic neurons [<xref ref-type="bibr" rid="RSOB170216C9">9</xref>]. RTT patients show evidence of dysregulated neurotransmitters, neuromodulators and transporters, indicating an important role in synaptic function [<xref ref-type="bibr" rid="RSOB170216C13">13</xref>,<xref ref-type="bibr" rid="RSOB170216C14">14</xref>].</p>
<p>Metabolic complications are also common in RTT. A number of patients present with dyslipidaemia [<xref ref-type="bibr" rid="RSOB170216C15">15</xref>,<xref ref-type="bibr" rid="RSOB170216C16">16</xref>], elevated plasma leptin and adiponectin [<xref ref-type="bibr" rid="RSOB170216C17">17</xref>,<xref ref-type="bibr" rid="RSOB170216C18">18</xref>], elevated ammonia [<xref ref-type="bibr" rid="RSOB170216C1">1</xref>] and inflammation of the gallbladder, an organ which stores bile for fat digestion [<xref ref-type="bibr" rid="RSOB170216C19">19</xref>]. Changes in brain carbohydrate metabolism [<xref ref-type="bibr" rid="RSOB170216C20">20</xref>] and neurometabolites associated with cell integrity and membrane turnover [<xref ref-type="bibr" rid="RSOB170216C21">21</xref>,<xref ref-type="bibr" rid="RSOB170216C22">22</xref>] have also been reported. Additionally, energy-producing mitochondria have abnormal structure in patient cells [<xref ref-type="bibr" rid="RSOB170216C23">23</xref>–<xref ref-type="bibr" rid="RSOB170216C26">26</xref>]. Consistently, altered electron transport chain complex function [<xref ref-type="bibr" rid="RSOB170216C27">27</xref>], increased oxidative stress [<xref ref-type="bibr" rid="RSOB170216C28">28</xref>–<xref ref-type="bibr" rid="RSOB170216C30">30</xref>], and elevated levels of lactate and pyruvate in blood and cerebrospinal fluid [<xref ref-type="bibr" rid="RSOB170216C20">20</xref>,<xref ref-type="bibr" rid="RSOB170216C27">27</xref>] have been observed in RTT patients (reviewed in [<xref ref-type="bibr" rid="RSOB170216C31">31</xref>]).</p>
<p>Treatment for RTT patients is currently limited to symptom control. With adequate attention to orthopaedic complications, seizure control and nutrition, women with RTT may survive into middle age and older. However, patients have a sudden and unexpected death rate of 26%, much higher than healthy individuals of a similar age, and typically die due to respiratory infection, cardiac instability and respiratory failure [<xref ref-type="bibr" rid="RSOB170216C32">32</xref>–<xref ref-type="bibr" rid="RSOB170216C34">34</xref>].</p>
</sec>
<sec id="s2">
<label>2.</label>
<title>Mutations in <italic>MECP2</italic> cause Rett syndrome</title>
<p>Familial cases were instrumental in determining the genetic cause of typical RTT. Multipoint linkage analysis of a Brazilian RTT family with three affected and three unaffected daughters narrowed the location of the gene to Xq28 [<xref ref-type="bibr" rid="RSOB170216C35">35</xref>]. Following this breakthrough in 1999, Amir <italic>et al</italic>. [<xref ref-type="bibr" rid="RSOB170216C36">36</xref>] systematically analysed nearly 100 candidate genes located in the Xq28 region for mutations in RTT patients. By screening genomic DNA from sporadic and familial RTT patients, the group identified damaging missense, frameshift and nonsense mutations in the coding region of the gene methyl-CpG-binding protein 2 (<italic>MECP2</italic>) in seven patients. It is now well established that mutations in <italic>MECP2</italic> account for 95% of typical RTT cases and commonly occur <italic>de novo</italic> [<xref ref-type="bibr" rid="RSOB170216C36">36</xref>–<xref ref-type="bibr" rid="RSOB170216C38">38</xref>]. RTT patients are heterozygous for <italic>MECP2</italic> mutation, carrying one normal and one mutated copy of <italic>MECP2.</italic> When a child presents with RTT-like symptoms, but does not fulfil all the diagnostic criteria for RTT, they may be diagnosed with atypical RTT, symptoms of which deviate in age of onset, sequence of clinical profile and/or severity (<xref ref-type="table" rid="RSOB170216TB1">table 1</xref>) [<xref ref-type="bibr" rid="RSOB170216C39">39</xref>–<xref ref-type="bibr" rid="RSOB170216C49">49</xref>]. Many atypical cases are associated with mutations in X-linked cyclin-dependent kinase-like 5 (<italic>CDKL5</italic>; OMIM #300203) or Forkhead box G1 (<italic>FOXG1</italic>; OMIM #164874), but some remain undefined [<xref ref-type="bibr" rid="RSOB170216C39">39</xref>–<xref ref-type="bibr" rid="RSOB170216C49">49</xref>]. Mutations in <italic>MECP2</italic> have also been associated with intellectual disability, autism and lupus erythematosis [<xref ref-type="bibr" rid="RSOB170216C50">50</xref>,<xref ref-type="bibr" rid="RSOB170216C51">51</xref>].
<table-wrap id="RSOB170216TB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Atypical Rett syndrome variants. These variants may be milder or more severe than classical RTT symptoms.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1">type</th><th align="left" colspan="1" rowspan="1">description</th></tr></thead><tbody><tr><td colspan="2" rowspan="1"><bold>severe atypical RTT variants</bold></td></tr><tr><td colspan="1" rowspan="1">early-onset seizure type</td><td colspan="1" rowspan="1">— can be caused by mutation in X-linked cyclin-dependent kinase-like five gene (CDKL5; OMIM #300203)<break></break>— seizures in the first months of life <break></break>— develop RTT symptoms</td></tr><tr><td colspan="1" rowspan="1">congenital variant</td><td colspan="1" rowspan="1">— can be caused by mutation in the Forkhead box G1 (FOXG1; OMIM #164874) gene located on chromosome 14<break></break>— born with congenital microcephaly and intellectual disability<break></break>— lack of normal psychomotor development<break></break>— develop RTT symptoms during first three months of life</td></tr><tr><td colspan="2" rowspan="1"><bold>milder atypical RTT variants</bold></td></tr><tr><td colspan="1" rowspan="1">late regression type</td><td colspan="1" rowspan="1">— develop RTT symptoms at a preschool age</td></tr><tr><td colspan="1" rowspan="1">preserved speech ‘Zapella’ type</td><td colspan="1" rowspan="1">— develop RTT symptoms but recover some verbal skills and can form phrases and sentences</td></tr><tr><td colspan="1" rowspan="1">‘Forme fruste’ variant</td><td colspan="1" rowspan="1">— the most common atypical variant accounting for 80% of cases <break></break>well-preserved motor skills and only subtle neurological abnormalities such as mild hand dyspraxia</td></tr></tbody></table></table-wrap></p>
<p>MeCP2 is an abundant nuclear protein that was originally identified in a screen for proteins with methyl-DNA-specific binding activity. It is ubiquitously expressed throughout all human tissues, but is particularly abundant within neurons [<xref ref-type="bibr" rid="RSOB170216C52">52</xref>,<xref ref-type="bibr" rid="RSOB170216C53">53</xref>]. In the central nervous system (CNS), MeCP2 is expressed at low levels prenatally, but progressively increases during neuronal maturation and synaptogenesis reaching its peak in mature, post-migratory neurons, suggesting a role for MeCP2 in maintaining neuronal maturation, activity and plasticity [<xref ref-type="bibr" rid="RSOB170216C54">54</xref>–<xref ref-type="bibr" rid="RSOB170216C57">57</xref>].</p>
<p><italic>MECP2</italic> is encoded by four exons which are expressed as the MeCP2_exon1 (e1) and the MeCP2_exon2 (e2) isoforms (<xref ref-type="fig" rid="RSOB170216F2">figure 2</xref><italic>a</italic>) [<xref ref-type="bibr" rid="RSOB170216C57">57</xref>–<xref ref-type="bibr" rid="RSOB170216C59">59</xref>]. MeCP2_e1 is 10 times more abundant than MeCP2_e2 in human and mouse brain and in mouse thymus and lung, whereas a 1 : 1 ratio is seen in mouse testis and liver [<xref ref-type="bibr" rid="RSOB170216C60">60</xref>,<xref ref-type="bibr" rid="RSOB170216C61">61</xref>], suggesting that e1 is the primary functional isoform in the brain. Exon 4 in both mouse and human contains an 8.5 kb 3′UTR, which is one of the longest known in the human genome, and features four polyadenylation (polyA) sites resulting in four differentially expressed transcripts (<xref ref-type="fig" rid="RSOB170216F2">figure 2</xref><italic>a</italic>) [<xref ref-type="bibr" rid="RSOB170216C62">62</xref>–<xref ref-type="bibr" rid="RSOB170216C64">64</xref>]. The 3′UTR may regulate downstream translation of <italic>MECP2</italic>'s transcript by controlling mRNA degradation and stability, nucleocytoplasmic transport, mRNA localization and modulation of translation [<xref ref-type="bibr" rid="RSOB170216C65">65</xref>]. The alternate <italic>MECP2</italic> transcripts show quantitative differences in expression in different tissues, in different stages of mouse embryonic development and in human post-natal brain development [<xref ref-type="bibr" rid="RSOB170216C62">62</xref>].
<fig id="RSOB170216F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Mutations in the multifunctional protein MeCP2 cause RTT. Coloured boxes indicate different encoded functional domains: light orange, N-terminus of MeCP2_e1; dark orange, N-terminus of MeCP2_e2; green, N-terminal domain (NTD) which has identical amino acid sequences between the two isoforms; pink, methyl-binding domain (MBD); blue, transcriptional repression domain (TRD); red, nuclear coreceptor co-repressor (NCoR) interaction domain (NID); yellow, C-terminal domain (CTD). (<italic>a</italic>) The four exons in the <italic>MECP2</italic> gene. Arrows in exons 1 and 2 indicate the ‘ATG’ start codons for MeCP2_e1 or MeCP2_e2, respectively. Arrows in the 3′ UTR indicate multiple polyA sites resulting in different-length transcripts. Dashed lines on the top indicate the splicing pattern of MeCP2_e1 and dashed lines on the bottom indicate the splicing pattern of MeCP2_e2. (<italic>b</italic>) Functional domains and post-translational modifications (PTMs) of MeCP2. Coordinates are in relation to isoform MeCP2_e2. MeCP2 contains two PEST domains (black slashed boxes), two HMG domains (blue slashed boxes), three AT-hook domains (black solid boxes), one functional nuclear localization signal (NLS) (pink slashed box) and one WW domain (orange slashed box). PTMs are scattered throughout the protein and regulate interactions with MeCP2 binding partners. (<italic>c</italic>) Common damaging <italic>MECP2</italic> mutations. Schematic of MeCP2 with functional domains. <italic>y</italic>-axis represents percentage of RTT patients with indicated mutation. Missense mutations are in purple and nonsense mutations are in red. Combined, these point mutations make up approximately 70% of all RTT-causing mutations.</p></caption><graphic xlink:href="rsob-8-170216-g2"></graphic></fig></p>
<p>MeCP2 consists of four primary functional domains (<xref ref-type="fig" rid="RSOB170216F2">figure 2</xref><italic>b</italic>). The binding specificity of MeCP2 is dependent on the presence of methylated DNA and its methyl-binding domain (MBD) located at amino acids 78–162 [<xref ref-type="bibr" rid="RSOB170216C53">53</xref>,<xref ref-type="bibr" rid="RSOB170216C66">66</xref>]. MeCP2 is different from other methyl-DNA binding proteins because of its ability to interact with a single, symmetrical methylated CpG (mCpG) site [<xref ref-type="bibr" rid="RSOB170216C53">53</xref>,<xref ref-type="bibr" rid="RSOB170216C66">66</xref>]. However, recent work by Lagger <italic>et al.</italic> revealed that MeCP2 also has a high binding affinity for methylated and hydroxymethylated CAC (mCAC and hmCAC, respectively) in neurons, demonstrating that both methylated dinucleotides and trinucleotides can recruit MeCP2 to DNA for transcriptional regulation [<xref ref-type="bibr" rid="RSOB170216C67">67</xref>]. A transcriptional repressor domain (TRD) occurs in amino acids 207–310, and contains the NCoR-interaction domain (NID), which facilitates binding of MeCP2 to the NCoR1/SMRT co-repressor complex [<xref ref-type="bibr" rid="RSOB170216C68">68</xref>–<xref ref-type="bibr" rid="RSOB170216C71">71</xref>]. The C-terminal domain (CTD) also shows DNA-binding ability, suggesting the presence of a chromatin-interacting domain in the vicinity of the 5′ region of the CTD [<xref ref-type="bibr" rid="RSOB170216C72">72</xref>].</p>
<p>CpG methylation is minimal in invertebrate genomes (10–40%), but very high in vertebrate genomes (60–90%) [<xref ref-type="bibr" rid="RSOB170216C73">73</xref>,<xref ref-type="bibr" rid="RSOB170216C74">74</xref>]. Methylated DNA sites recruit methyl-DNA-binding proteins like MeCP2, which attract transcriptional regulatory complexes [<xref ref-type="bibr" rid="RSOB170216C75">75</xref>]. Consistently, MeCP2 represses transcription in a gene-specific manner, interacting with the co-repressor complexes mSIN3A and NCoR1/SMRT [<xref ref-type="bibr" rid="RSOB170216C70">70</xref>,<xref ref-type="bibr" rid="RSOB170216C76">76</xref>]. However, MeCP2 may also facilitate transcriptional activation [<xref ref-type="bibr" rid="RSOB170216C77">77</xref>], chromatin compaction [<xref ref-type="bibr" rid="RSOB170216C78">78</xref>,<xref ref-type="bibr" rid="RSOB170216C79">79</xref>] and mRNA splicing [<xref ref-type="bibr" rid="RSOB170216C80">80</xref>,<xref ref-type="bibr" rid="RSOB170216C81">81</xref>], while also interacting with a host of other regulatory proteins involved in a variety of molecular pathways [<xref ref-type="bibr" rid="RSOB170216C81">81</xref>–<xref ref-type="bibr" rid="RSOB170216C84">84</xref>].</p>
<p>Despite having well-defined functional domains, MeCP2 classifies as an intrinsically disordered protein (IDP) and acquires tertiary structure upon interaction with other protein partners or nucleic acids [<xref ref-type="bibr" rid="RSOB170216C85">85</xref>]. Disordered structure makes IDPs notoriously promiscuous binding partners [<xref ref-type="bibr" rid="RSOB170216C86">86</xref>]. As such, post-translational modifications (PTMs) add an additional layer of regulation to ensure MeCP2 binding to appropriate partners. Accordingly, MeCP2 undergoes many PTMs including acetylation, phosphorylation, ubiquitination and SUMOylation (<xref ref-type="fig" rid="RSOB170216F2">figure 2</xref><italic>b</italic>; reviewed in [<xref ref-type="bibr" rid="RSOB170216C87">87</xref>,<xref ref-type="bibr" rid="RSOB170216C88">88</xref>]), which strongly regulate interactions. Altogether, multiple studies suggest that genes can be activated or repressed by MeCP2, depending upon the cellular context [<xref ref-type="bibr" rid="RSOB170216C77">77</xref>,<xref ref-type="bibr" rid="RSOB170216C89">89</xref>,<xref ref-type="bibr" rid="RSOB170216C90">90</xref>], suggesting that MeCP2 may be defined as a transcriptional modulator.</p>
</sec>
<sec id="s3">
<label>3.</label>
<title>Phenotype variation among people with <italic>MECP2</italic> mutations</title>
<p>According to the Human Gene Mutation database, 555 RTT-causing mutations have been identified in <italic>MECP2</italic> [<xref ref-type="bibr" rid="RSOB170216C91">91</xref>]<italic>. De novo</italic> mutations account for 99.5% of the mutations in <italic>MECP2</italic>, of which approximately 70% are C &gt; T transitions, which typically arise due to hypermutability at mCpG dinucleotides within the <italic>MECP2</italic> locus [<xref ref-type="bibr" rid="RSOB170216C48">48</xref>]. Unlike the X chromosome in oocytes, the X chromosome in sperm is hypermethylated. It has been speculated that spontaneous deamination of methylated cytosine residues may result in a transition to a thymine, increasing the potential for deleterious mutations at hypermethylated CpG sites [<xref ref-type="bibr" rid="RSOB170216C92">92</xref>,<xref ref-type="bibr" rid="RSOB170216C93">93</xref>]. As such, most <italic>de novo MECP2</italic> mutations originate from the paternally inherited X chromosome [<xref ref-type="bibr" rid="RSOB170216C94">94</xref>].</p>
<p>The wide spectrum of <italic>MECP2</italic> mutations includes point mutations, insertions, duplications, small or large deletions, or whole <italic>MECP2</italic> gene deletions. Despite this, only eight missense and nonsense mutations (R106 W, R133C, T158M, R168X, R255X, R270X, R294X and R306C) account for approximately 70% of all mutations in RTT (<xref ref-type="fig" rid="RSOB170216F2">figure 2</xref><italic>c</italic>). C-terminal deletions account for another approximately 8%, and large deletions constitute approximately 5% [<xref ref-type="bibr" rid="RSOB170216C38">38</xref>]. Mutation types tend to cluster: missense mutations frequently occur in the MBD, while nonsense mutations generally occur downstream of the MBD [<xref ref-type="bibr" rid="RSOB170216C38">38</xref>]. Frameshift mutations resulting from small deletions usually occur in the C-terminus (<xref ref-type="fig" rid="RSOB170216F2">figure 2</xref><italic>c</italic>) [<xref ref-type="bibr" rid="RSOB170216C48">48</xref>]. The location of the mutation reduces specific aspects of MeCP2 function [<xref ref-type="bibr" rid="RSOB170216C95">95</xref>]. For example, mutations located in the MBD reduce the DNA-binding ability of MeCP2.</p>
<p>In early studies, Hagberg <italic>et al</italic>. [<xref ref-type="bibr" rid="RSOB170216C2">2</xref>] noted that the severity of motor impairment in classic female RTT patients ranged from wheelchair bound before age five to retaining the ability to walk with a Parkinsonian-like gait. Given the wide variety of mutation types and phenotype severity, genotype–phenotype studies have correlated mutation status with clinical features of RTT patients [<xref ref-type="bibr" rid="RSOB170216C38">38</xref>]. Early truncating mutations in the <italic>MECP2</italic> gene such as R168X, R255X and R270X, and large INDELs, cause the most severe phenotype. Missense mutations such as R133C and R306C, late truncating mutations such as those in R294X, and others in the 3′ end, which keep the MBD and most of the TRD intact, are the mildest [<xref ref-type="bibr" rid="RSOB170216C38">38</xref>,<xref ref-type="bibr" rid="RSOB170216C96">96</xref>]. Therefore, <italic>MECP2</italic> mutation status is a strong predictor of disease severity, but phenotype variation commonly occurs between individuals with the same <italic>MECP2</italic> mutation and is attributed to differences in X chromosome inactivation (XCI) [<xref ref-type="bibr" rid="RSOB170216C97">97</xref>].</p>
<p>Female heterozygous RTT patients are mosaic, allowing some cells to express the mutant <italic>MECP2,</italic> while the others express the wild-type allele. XCI can be skewed preferentially so the mutant X chromosome is more or less expressed than the wild type, resulting in either a relatively more severe or milder presentation of RTT, respectively [<xref ref-type="bibr" rid="RSOB170216C98">98</xref>,<xref ref-type="bibr" rid="RSOB170216C99">99</xref>]. The mother of the children in the original Brazilian family presented no symptoms because her X-inactivation footprint skewed 95% of expression from the non-mutated chromosome [<xref ref-type="bibr" rid="RSOB170216C35">35</xref>]. Interestingly, several patients with the same mutation may exhibit a broad spectrum of clinical severity despite similar patterns of XCI in peripheral blood, potentially due to second gene mutations (modifiers) that alleviate or enhance the phenotypic outcome of <italic>MECP2</italic> mutation [<xref ref-type="bibr" rid="RSOB170216C100">100</xref>].</p>
<p>As an X-linked disorder, RTT was considered to be lethal in males. However, males with clinical features resembling classical RTT were reported even before the discovery of the causal gene. In 1999, Wan <italic>et al</italic>. [<xref ref-type="bibr" rid="RSOB170216C37">37</xref>] described the first mutation in <italic>MECP2</italic> in a male patient who died at one year of age from congenital neonatal encephalopathy. This discovery prompted the inclusion of boys in screening for <italic>MECP2</italic> mutations, allowing them to be classified into four categories: severe neonatal encephalopathy and infantile death, typical RTT, less severe neuropsychiatric phenotypes or <italic>MECP2</italic> duplication syndrome (<xref ref-type="table" rid="RSOB170216TB2">table 2</xref>) [<xref ref-type="bibr" rid="RSOB170216C101">101</xref>–<xref ref-type="bibr" rid="RSOB170216C108">108</xref>].
<table-wrap id="RSOB170216TB2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Males with <italic>MECP2</italic> mutations fall into four categories.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1">category</th><th align="left" colspan="1" rowspan="1"><italic>MECP2</italic> profile</th><th align="left" colspan="1" rowspan="1">features</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">severe neonatal encephalopathy and infantile death</td><td colspan="1" rowspan="1"><italic>MECP2</italic> mutation passed on by mildly symptomatic or asymptomatic mother</td><td colspan="1" rowspan="1">— spontaneously miscarried <break></break>— if born, develop neonatal encephalopathy, respiratory arrest and seizures, death within 2 years</td></tr><tr><td colspan="1" rowspan="1">classical RTT</td><td colspan="1" rowspan="1">have at least partial Klinefelter's syndrome (XXY karyotype) or other somatic mosaicism</td><td colspan="1" rowspan="1">— symptoms similar to female RTT patients</td></tr><tr><td colspan="1" rowspan="1">less severe neuropsychiatric symptoms</td><td colspan="1" rowspan="1"><italic>MECP2</italic> mutations are less severe than those in female RTT patients</td><td colspan="1" rowspan="1">— symptoms are broad and overlap with features of Angelman syndrome (intellectual disability and motor abnormalities)</td></tr><tr><td colspan="1" rowspan="1"><italic>MECP2</italic> duplication syndrome</td><td colspan="1" rowspan="1">gain of <italic>MECP2</italic> dosage</td><td colspan="1" rowspan="1">— hypotonia, severe intellectual disability, recurrent lung infections, absent or limited speech and walking, seizures, motor spasticity and muscle stiffness<break></break>— 50% die before age 25</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="s4">
<label>4.</label>
<title>Animal models inform <italic>MECP2</italic> function</title>
<p><italic>MECP2</italic> appears across vertebrate evolution with strong conservation in its functional domains. <italic>Drosophila</italic> do not possess an orthologue to human <italic>MECP2</italic>, perhaps because the invertebrate genome is sparsely methylated [<xref ref-type="bibr" rid="RSOB170216C109">109</xref>]. In 2013, Pietri <italic>et al</italic>. isolated the first null <italic>mecp2<sup>Q63*/Q63*</sup></italic> zebrafish model, which does not recapitulate features of the human disorder [<xref ref-type="bibr" rid="RSOB170216C110">110</xref>,<xref ref-type="bibr" rid="RSOB170216C111">111</xref>]. Instead, the fish are viable and reproduce normally, but display minor motor abnormalities and a shortened lifespan, possibly due to immune deficiencies [<xref ref-type="bibr" rid="RSOB170216C112">112</xref>]. In 2017, Chen <italic>et al</italic>. [<xref ref-type="bibr" rid="RSOB170216C113">113</xref>] published the first analysis of <italic>MECP2-</italic>mutant cynomolgus monkeys, which exhibit decreased movement, social withdrawal, increased stereotypical behaviour and sleep abnormalities—symptoms common in RTT patients [<xref ref-type="bibr" rid="RSOB170216C113">113</xref>]. Overall, the monkeys exhibit CNS and transcriptome changes that are consistent with the human, in spite of being genetically heterogeneous [<xref ref-type="bibr" rid="RSOB170216C113">113</xref>]. Therefore, simian models may serve as a robust, albeit expensive, system to study sophisticated features of RTT in the future.</p>
<p><italic>Mecp2</italic> mutant rodents recapitulate many hallmark symptoms of RTT and are the most widely accepted tool to study the disorder. An engineered null rat model of RTT (<italic>Mecp2<sup>ZFN</sup></italic>) shows phenotypic and transcriptomic similarities to mouse models [<xref ref-type="bibr" rid="RSOB170216C114">114</xref>–<xref ref-type="bibr" rid="RSOB170216C116">116</xref>]. Although rats would have advantages for physiologic and preclinical testing, they are not used widely, perhaps due to their cost and the lack of genetic tools. Instead, two null mouse alleles are the primary models for Rett syndrome (<xref ref-type="table" rid="RSOB170216TB3">table 3</xref>). The Bird laboratory developed a <italic>Mecp2</italic> mutant mouse model by engineering <italic>lox</italic>P sites flanking <italic>Mecp2</italic> exons 3 and 4 to create a ‘floxed’ conditional line [<xref ref-type="bibr" rid="RSOB170216C117">117</xref>]. This conditional-ready allele, called <italic>Mecp2<sup>tm1Bird</sup></italic>, is hypomorphic, resulting in mild RTT-like symptoms due to a 50% reduction in MeCP2 expression [<xref ref-type="bibr" rid="RSOB170216C118">118</xref>,<xref ref-type="bibr" rid="RSOB170216C119">119</xref>]. A null mouse line lacking any protein product was created by crossing with a germline-deleting Cre driver (<italic>Mecp2<sup>tm1.1Bird</sup></italic>/Y) [<xref ref-type="bibr" rid="RSOB170216C117">117</xref>]. Simultaneously, the Jaenisch lab designed a <italic>Mecp2</italic> mutant mouse by engineering <italic>lox</italic>P sites flanking exon 3, <italic>Mecp2<sup>tm1.1Jae</sup></italic> [<xref ref-type="bibr" rid="RSOB170216C120">120</xref>]<italic>.</italic> A smaller <italic>Mecp2</italic> transcript and protein fragments are present in mutant brain; however, these mice show phenotypes similar to the null Bird allele.
<table-wrap id="RSOB170216TB3" orientation="portrait" position="float"><label>Table 3.</label><caption><p><italic>Mecp2</italic> mutant mouse models. The <italic>Mecp2<sup>tm1.1Bird</sup></italic> and <italic>Mecp2<sup>tm1.1Jae</sup></italic> alleles are the most commonly studied. Point mutation alleles are designed to mimic human RTT-causing mutations. Many conditional deletions have been created, but are not summarized here.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1">allele type</th><th align="left" colspan="1" rowspan="1">allele description</th><th align="left" colspan="1" rowspan="1">phenotypes</th><th align="left" colspan="1" rowspan="1">death (males)</th><th align="left" colspan="1" rowspan="1">reference</th></tr></thead><tbody><tr><td colspan="5" rowspan="1"><bold>null alleles</bold></td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1.1Bird</sup></italic></td><td colspan="1" rowspan="1">deletion of exon 3–4</td><td colspan="1" rowspan="1">stiff gait, reduced movement, hindlimb clasp, tremors, dishevelled fur, B6 underweight, 129 overweight</td><td colspan="1" rowspan="1">7–10 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C79">79</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1.1Jae</sup></italic></td><td colspan="1" rowspan="1">deletion of exon 3<sup>a</sup></td><td colspan="1" rowspan="1">abnormal gait, hypoactive, tremors, mixed reports on weight</td><td colspan="1" rowspan="1">10 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C82">82</xref>]</td></tr><tr><td colspan="5" rowspan="1"><bold>point mutation alleles</bold></td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1Hzo</sup></italic></td><td colspan="1" rowspan="1">R308X; truncation</td><td colspan="1" rowspan="1">ataxia, tremors, dishevelled fur</td><td colspan="1" rowspan="1">&gt;1 year</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C89">89</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1.1Jtc</sup></italic></td><td colspan="1" rowspan="1">R168X; truncation</td><td colspan="1" rowspan="1">hypoactive, hindlimb atrophy and clasping, breathing irregularities</td><td colspan="1" rowspan="1">12–14 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C90">90</xref>,<xref ref-type="bibr" rid="RSOB170216C91">91</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm2.1Jae</sup></italic></td><td colspan="1" rowspan="1">S80A; missense</td><td colspan="1" rowspan="1">motor defects, slightly overweight</td><td colspan="1" rowspan="1">&gt;1 year</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C48">48</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1Vnar</sup></italic></td><td colspan="1" rowspan="1">A140 V; missense</td><td colspan="1" rowspan="1">asymptomatic</td><td colspan="1" rowspan="1">&gt;1 year</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C92">92</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1.1Meg</sup></italic></td><td colspan="1" rowspan="1">S421A; missense</td><td colspan="1" rowspan="1">asymptomatic</td><td colspan="1" rowspan="1">&gt;1 year</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C93">93</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1.1Joez</sup></italic></td><td colspan="1" rowspan="1">T158A; missense</td><td colspan="1" rowspan="1">abnormal gait, hypoactive, hindlimb clasp, reduced weight</td><td colspan="1" rowspan="1">16 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C94">94</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1.1Mitoh</sup></italic></td><td colspan="1" rowspan="1">deletion of MeCP2 exon 2</td><td colspan="1" rowspan="1">asymptomatic but have placental defects</td><td colspan="1" rowspan="1">&gt;1 year</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C95">95</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm5.1Bird</sup></italic></td><td colspan="1" rowspan="1">R306C; missense</td><td colspan="1" rowspan="1">poor mobility, hindlimb clasping, tremors</td><td colspan="1" rowspan="1">18–25 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C44">44</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm3Meg</sup></italic></td><td colspan="1" rowspan="1">T308A; missense</td><td colspan="1" rowspan="1">poor mobility, hindlimb clasping</td><td colspan="1" rowspan="1">&gt;16 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C45">45</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1.1Dhy</sup></italic></td><td colspan="1" rowspan="1">deletion of MeCP2 exon 1</td><td colspan="1" rowspan="1">hypoactive, hindlimb clasping, excessive grooming</td><td colspan="1" rowspan="1">7–31 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C96">96</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm4.1Bird</sup></italic></td><td colspan="1" rowspan="1">T158M; missense</td><td colspan="1" rowspan="1">poor mobility, hindlimb clasping, tremors</td><td colspan="1" rowspan="1">13 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C97">97</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm6.1 Bird</sup></italic></td><td colspan="1" rowspan="1">R133C; missense</td><td colspan="1" rowspan="1">poor mobility, hindlimb clasping, tremors</td><td colspan="1" rowspan="1">42 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C97">97</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1.1Irsf</sup></italic></td><td colspan="1" rowspan="1">R255X; nonsense</td><td colspan="1" rowspan="1">breathing irregularities, heart defects</td><td colspan="1" rowspan="1">8–10 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C98">98</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm3.1Joez</sup></italic></td><td colspan="1" rowspan="1">T158M; missense</td><td colspan="1" rowspan="1">abnormal gait, poor mobility, breathing irregularities, underweight</td><td colspan="1" rowspan="1">13 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C99">99</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm4.1Joez</sup></italic></td><td colspan="1" rowspan="1">R106 W; missense</td><td colspan="1" rowspan="1">hypoactive, hindlimb clasping, underweight</td><td colspan="1" rowspan="1">10 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C100">100</xref>]</td></tr><tr><td colspan="5" rowspan="1"><bold>conditional alleles</bold></td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1Bird</sup></italic></td><td colspan="1" rowspan="1">floxed exons 3–4;<break></break>hypomorphic</td><td colspan="1" rowspan="1">mild phenotype similar to <italic>Mecp2<sup>tm1.1Bird</sup></italic> with delayed onset</td><td colspan="1" rowspan="1">as wild-type</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C79">79</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm1Jae</sup></italic></td><td colspan="1" rowspan="1">floxed exon 3</td><td colspan="1" rowspan="1">no phenotype</td><td colspan="1" rowspan="1">as wild-type</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C82">82</xref>]</td></tr><tr><td colspan="1" rowspan="1"><italic>Mecp2<sup>tm2Bird</sup></italic></td><td colspan="1" rowspan="1">floxed stop upstream exon 3</td><td colspan="1" rowspan="1">identical to <italic>Mecp2<sup>tm1.1Bird</sup></italic></td><td colspan="1" rowspan="1">10 weeks</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB170216C106">106</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup>Some protein product retained.</p></fn></table-wrap-foot></table-wrap></p>
<p>Although RTT predominantly affects girls, the vast majority of published mouse studies take place in hemizygous <italic>Mecp2</italic> mutant male mice, because they present with a more consistent phenotype early in life. While female <italic>Mecp2</italic> mutant mice are more clinically relevant, random XCI in rodent females causes skewing of gene expression, resulting in large variations in phenotype presentation, making it difficult to separate which phenotypes arise through cell autonomous versus non-autonomous pathways [<xref ref-type="bibr" rid="RSOB170216C121">121</xref>]. The most commonly used male mouse models, <italic>Mecp2<sup>tm1.1Bird</sup></italic> and <italic>Mecp2<sup>tm1.1Jae</sup></italic>, consistently display overt phenotypes at four to six weeks of age, and die between 8 and 12 weeks of age [<xref ref-type="bibr" rid="RSOB170216C117">117</xref>,<xref ref-type="bibr" rid="RSOB170216C120">120</xref>]. Though <italic>Mecp2</italic> null mice are asymptomatic prior to four weeks of age, there are subtle but consistent defects in transcription, ionotropic receptor signalling, and neuronal responsiveness during late embryogenesis and the perinatal period [<xref ref-type="bibr" rid="RSOB170216C122">122</xref>–<xref ref-type="bibr" rid="RSOB170216C124">124</xref>]. At four weeks of age, null mice begin to develop uncoordinated gait, hypoactivity, tremors, hindlimb clasping reminiscent of the hand stereotypies seen in RTT patients, and irregular breathing. These phenotypes progress in severity until death. The soma and nuclei of <italic>Mecp2</italic> mutant neurons in the hippocampus, cerebral cortex and cerebellum are smaller and more densely packed than in wild-type littermates, probably giving rise to a smaller brain [<xref ref-type="bibr" rid="RSOB170216C120">120</xref>].</p>
<p>Curiously, body weight in <italic>Mecp2</italic> null mice differs depending on genetic background; male <italic>Mecp2<sup>tm1.1Bird</sup></italic>/Y mice on a C57BL/6J background are substantially underweight by four weeks of age compared with wild-type littermates. On a 129S6/SvEvTac strain, males show a reverse effect: <italic>Mecp2<sup>tm1.1Bird</sup></italic>/Y mice are the same weight as wild-type littermates until eight weeks of age, when they become significantly heavier than siblings [<xref ref-type="bibr" rid="RSOB170216C117">117</xref>]. Lastly, <italic>Mecp2<sup>tm1.1Bird</sup>/</italic>Y mice on a CD1 background weigh slightly less than wild type early in life, but reach a normal weight by six to seven weeks of age [<xref ref-type="bibr" rid="RSOB170216C125">125</xref>].</p>
<p>Heterozygous female mice also show no symptoms initially, but become hypoactive and start to hindlimb clasp at three months. By nine months of age, approximately 50% of heterozygous females develop the same phenotypes as their null counterparts, but some females remain asymptomatic at 1 year. Therefore, females have a lifespan that allows for reproduction, suggesting that the heterozygous condition can exhibit long-term stability, as seen in RTT [<xref ref-type="bibr" rid="RSOB170216C117">117</xref>]. Interestingly, heterozygous female mice on all genetic backgrounds, as well as female rats, become significantly overweight as they age [<xref ref-type="bibr" rid="RSOB170216C115">115</xref>,<xref ref-type="bibr" rid="RSOB170216C117">117</xref>,<xref ref-type="bibr" rid="RSOB170216C125">125</xref>], although humans with RTT have a wide range in body mass index [<xref ref-type="bibr" rid="RSOB170216C15">15</xref>].</p>
<p>In addition to deletion mouse models, several alleles have been engineered to recapitulate clinically relevant and common <italic>MECP2</italic> mutations in human patients. Mice with these alleles tend to display milder and later onset neurological phenotypes compared with the <italic>Mecp2<sup>tm1.1Bird</sup></italic> null allele, and most do not recapitulate the entire disease phenotype (summarized in <xref ref-type="table" rid="RSOB170216TB3">table 3</xref>) [<xref ref-type="bibr" rid="RSOB170216C70">70</xref>,<xref ref-type="bibr" rid="RSOB170216C71">71</xref>,<xref ref-type="bibr" rid="RSOB170216C126">126</xref>–<xref ref-type="bibr" rid="RSOB170216C138">138</xref>]. In an effort to distinguish the cause of specific phenotypes, <italic>Mecp2</italic> has also been conditionally deleted from different cell types and tissues [<xref ref-type="bibr" rid="RSOB170216C139">139</xref>–<xref ref-type="bibr" rid="RSOB170216C142">142</xref>]. A number of conditional deletions in different subsets of neurons highlight the essential role of MeCP2 in neuronal function, yet their milder presentation suggests additional roles outside the CNS (reviewed in [<xref ref-type="bibr" rid="RSOB170216C143">143</xref>]).</p>
<p>RTT patients show abnormal neuronal morphology, but not neuronal death, giving legitimacy to the possibility that defective MeCP2-deficient cells can recover [<xref ref-type="bibr" rid="RSOB170216C144">144</xref>]. In a landmark study, Guy <italic>et al.</italic> achieved symptom reversal in <italic>Mecp2</italic> mutant mice following the onset of motor dysfunction and neurological deficits. The <italic>Mecp2<sup>tm2Bird</sup></italic> ‘<italic>FloxedStop</italic>’ allele, in which a <italic>lox</italic>P-STOP-Neo-<italic>lox</italic>P cassette was inserted into the intron upstream of endogenous <italic>Mecp2</italic> exon 3, was crossed with mice carrying a Cre recombinase fused to the oestrogen receptor (OR). Injection of tamoxifen (TM) caused Cre-ER to translocate to the nucleus and delete the FloxedStop cassette to reactivate the <italic>Mecp2</italic> gene [<xref ref-type="bibr" rid="RSOB170216C145">145</xref>]. <italic>FloxedStop</italic>/Y male mice behaved like <italic>Mecp2<sup>tm1.1Bird</sup></italic>/Y mice, developed RTT-like symptoms between four and six weeks of age, and survived for approximately 10 weeks on average. TM injections in mice with advanced neurological symptoms and breathing abnormalities restored <italic>Mecp2</italic> expression to 80% of wild-type levels. Remarkably, restoration of MeCP2 expression reversed symptoms: neurological assessments and overall health improved and 80% of TM-treated animals survived beyond 30 weeks of age (end of study). Similarly, symptomatic <italic>FloxedStop</italic>/+ heterozygous female mice showed significant symptom improvement upon TM injection, including a reduction in body weight [<xref ref-type="bibr" rid="RSOB170216C145">145</xref>]. This pivotal finding showed that developmental absence of MeCP2 does not irreversibly damage neurons, instilling hope that symptom reversal is possible in RTT patients.</p>
</sec>
<sec id="s5">
<label>5.</label>
<title>MeCP2 modulates transcription by bridging DNA with regulatory complexes</title>
<p>In 2001, Kokura <italic>et al.</italic> [<xref ref-type="bibr" rid="RSOB170216C83">83</xref>] first demonstrated that MeCP2 binds to the NCoR1/SMRT co-repressor complex. NCoR1 and SMRT are highly homologous proteins that are recruited to chromatin to repress transcription by acting as a scaffold protein for other nuclear receptors, DNA-binding proteins and histone deacetylases [<xref ref-type="bibr" rid="RSOB170216C146">146</xref>]. One role of the NCoR1/SMRT complex is to recruit histone deacetylase 3 (HDAC3) to DNA, which removes histone acetyl marks, resulting in a closed chromatin state [<xref ref-type="bibr" rid="RSOB170216C147">147</xref>,<xref ref-type="bibr" rid="RSOB170216C148">148</xref>]. Other members of this complex include G protein pathway suppressor 2 (GPS2), transducin beta-like 1 (TBL1) and transducin beta-like 1 related (TBLR1) [<xref ref-type="bibr" rid="RSOB170216C149">149</xref>]. The interaction of MeCP2 with the NCoR1/SMRT complex was re-examined over a decade later when Lyst <italic>et al.</italic> [<xref ref-type="bibr" rid="RSOB170216C70">70</xref>] sought to identify binding partners of MeCP2. MeCP2 protein was purified from the brains of reporter mice with an enhanced green fluorescent protein (eGFP) inserted in the 3′ UTR of the <italic>Mecp2</italic> gene (<italic>Mecp2<sup>tm3.1Bird</sup></italic>) and mass spectrometry was used to identify associated proteins. Remarkably, five of the seven MeCP2 protein interactors identified were subunits of the NCoR1/SMRT co-repressor complex [<xref ref-type="bibr" rid="RSOB170216C70">70</xref>]. Furthermore, this group found that the interaction between MeCP2 and the NCoR1/SMRT complex was facilitated by the NCoR1/SMRT interaction domain (NID) located at MeCP2 amino acids 285–309 [<xref ref-type="bibr" rid="RSOB170216C70">70</xref>,<xref ref-type="bibr" rid="RSOB170216C71">71</xref>]. MeCP2 binds to complex members TBL1 and TBLR1 at these residues via a WD40 domain, unlike other NCoR1/SMRT recruiters which interact with the NCoR1/SMRT scaffold proteins directly [<xref ref-type="bibr" rid="RSOB170216C150">150</xref>]. These findings have led to a model wherein MeCP2 serves as a bridge between methylated DNA and the corepressor complex, anchoring the NCoR1/SMRT complex to DNA via its NID and MBD, respectively. It is hypothesized that disruption of this bridge leads to histone hyperacetylation and an open chromatin state, thereby increasing the transcription of target genes (<xref ref-type="fig" rid="RSOB170216F3">figure 3</xref>). Even so, transcriptional profiling studies using whole brain <italic>Mecp2</italic>/Y mice have not revealed dramatic gene expression changes [<xref ref-type="bibr" rid="RSOB170216C151">151</xref>,<xref ref-type="bibr" rid="RSOB170216C152">152</xref>], perhaps because the highly heterogeneous nature of the brain masks significant perturbations in subpopulations of cells.
<fig id="RSOB170216F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>MeCP2 anchors the NCoR/SMRT to methylated DNA. In healthy cells, MeCP2 binds methylated CpG dinucleotides (orange circles) and recruits the NCoR1/SMRT-HDAC3 co-repressor complex to regulatory sites surrounding the target loci. HDAC3 removes acetylation marks from surrounding histones to compact chromatin and prevent transcription of target genes. In <italic>Mecp2</italic> mutant cells, the NCOR1/SMRT-HDAC3 complex cannot bind to methylated DNA resulting in an open chromatin state and increased transcription of genes. Known target genes of the complex in the liver include <italic>Sqle</italic> and other lipogenesis enzymes. Targets in the brain remain unknown.</p></caption><graphic xlink:href="rsob-8-170216-g3"></graphic></fig></p>
<p>RTT-causing missense mutations cluster in the MBD and NID, highlighting the importance of these two regions of <italic>MECP2</italic> in RTT pathology [<xref ref-type="bibr" rid="RSOB170216C153">153</xref>]. Within the NID is a mutational hotspot of MeCP2 between amino acids 302 and 306 [<xref ref-type="bibr" rid="RSOB170216C70">70</xref>,<xref ref-type="bibr" rid="RSOB170216C154">154</xref>]. R306C is one of the more common RTT mutations, and this allele was modelled in mice to determine the biological relevance of the NCoR1 corepressor complex in RTT (<xref ref-type="table" rid="RSOB170216TB3">table 3</xref>) [<xref ref-type="bibr" rid="RSOB170216C68">68</xref>]. By six weeks of age, male <italic>Mecp2<sup>R306C</sup></italic> mice develop tremors, hypoactivity, hindlimb clasping and motor activity defects. Fifty per cent of <italic>Mecp2<sup>R306</sup></italic> mice fail to survive past 18-weeks of age and all die by 25 weeks [<xref ref-type="bibr" rid="RSOB170216C70">70</xref>]. The R306C mutant MeCP2 has an intact MBD, which binds to methylated heterochromatin. However, the mutation disables the NID, preventing MeCP2 from binding TBL1 or TBLR1, and thus the complex that contains NCoR1 and HDAC3, which disrupts MeCP2-mediated transcriptional repression. This suggests that the interruption of the MeCP2-NCoR1/SMRT complex interaction alone is capable of causing RTT-like phenotypes.</p>
<p>To test the primary role of the MeCP2-NCoR/SMRT1 interaction, the effect of a radically truncated MeCP2 protein was examined for symptom reversal in mice [<xref ref-type="bibr" rid="RSOB170216C155">155</xref>]. Mice were generated expressing a MeCP2 protein consisting of only the MBD, NID and short linker regions, while all other amino acid sequences of MeCP2 were removed. Remarkably, mice expressing this truncated protein develop only mild RTT-like symptoms and have a normal life span. Additionally, genetic re-activation or virus-mediated delivery of this minimal MeCP2 protein prevents or ameliorates symptoms in <italic>Mecp2-</italic>deficient pre-symptomatic or post-symptomatic mice, respectively. This suggests that a very important role of MeCP2 is to link DNA to the NCoR1/SMRT complex.</p>
</sec>
<sec id="s6">
<label>6.</label>
<title>A mouse mutagenesis screen links MeCP2 to lipid metabolism</title>
<p>While <italic>Mecp2</italic> mutant mice are an excellent model for RTT, elimination of MeCP2 affects the expression of a profound number of pathways in the CNS, making it difficult to pinpoint which ones play a key role in pathology [<xref ref-type="bibr" rid="RSOB170216C77">77</xref>,<xref ref-type="bibr" rid="RSOB170216C89">89</xref>,<xref ref-type="bibr" rid="RSOB170216C90">90</xref>]. For this reason, Buchovecky <italic>et al.</italic> [<xref ref-type="bibr" rid="RSOB170216C156">156</xref>] employed an unbiased forward genetic suppressor screen in <italic>Mecp2</italic> null mice to identify mutations that alleviate RTT symptoms, which could be exploited as potential treatment targets. Genetic screening is a powerful tool to detect pathways involved in disease aetiology independent of <italic>a priori</italic> assumptions. Curiously, a dominant nonsense mutation was found in squalene epoxidase (<italic>Sqle</italic>), a monooxygenase and rate-limiting cholesterol biosynthesis enzyme, which requires an electron donor from mitochondria for its function [<xref ref-type="bibr" rid="RSOB170216C157">157</xref>]. This mutation in <italic>Sqle</italic> improved RTT-like motor phenotypes, overall health and lifespan in <italic>Mecp2</italic> null male mice [<xref ref-type="bibr" rid="RSOB170216C156">156</xref>]. This sparked the question: is cholesterol metabolism perturbed in <italic>Mecp2</italic> mutant mice?</p>
<p>Cholesterol is a fundamental component of all cells [<xref ref-type="bibr" rid="RSOB170216C158">158</xref>,<xref ref-type="bibr" rid="RSOB170216C159">159</xref>]. While the liver is the primary manufacturer of cholesterol for the body, cholesterol is also a major component of the brain, where it functions in membrane trafficking, signal transduction, myelin formation, dendrite remodelling, neuropeptide formation and synaptogenesis [<xref ref-type="bibr" rid="RSOB170216C160">160</xref>]. Importantly, cholesterol cannot cross the blood–brain barrier (BBB), so any cholesterol that the brain requires must be synthesized <italic>in situ</italic> [<xref ref-type="bibr" rid="RSOB170216C161">161</xref>]. Therefore, the brain has complex and tightly regulated cholesterol synthesis pathways with multiple axes of self-regulation; too much or too little cholesterol is detrimental, and imparts negative consequences on cognition, memory and motor skills. To maintain homeostasis, cholesterol can be converted into the oxysterol 24(<italic>S</italic>)-hydroxycholesterol (24<italic>S-</italic>OHC) by the neuron-specific enzyme CYP46A1 (<xref ref-type="fig" rid="RSOB170216F4">figure 4</xref><italic>a</italic>) [<xref ref-type="bibr" rid="RSOB170216C162">162</xref>]. Oxysterols can pass lipophilic membranes more easily than cholesterol, allowing for one-way egress across the BBB and into the body [<xref ref-type="bibr" rid="RSOB170216C163">163</xref>].
<fig id="RSOB170216F4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Cholesterol metabolism is perturbed in <italic>Mecp2</italic> mutant mice. (<italic>a</italic>) In the wild-type mouse, the brain produces cholesterol <italic>in situ</italic> as cholesterol cannot pass the blood–brain barrier (BBB). Acetyl-CoA enters the cholesterol biosynthesis pathway to make cholesterol which has many essential functions (green triangles). The enzyme CYP46A1 converts excess cholesterol into 24<italic>S</italic>-hydroxycholesterol (24<italic>S</italic>-OHC) for one-way egress across the BBB. The liver participates in cholesterol biosynthesis to provide cholesterol to other tissues in the body. (<italic>b</italic>) In pre-symptomatic <italic>Mecp2</italic> null mice (3–4 weeks old), increased expression of cholesterol biosynthesis genes in the brain leads to elevated brain cholesterol levels. Consequently, the expression of <italic>Cyp46a1</italic> is increased, indicating a heightened need for cholesterol turnover. Outside of the central nervous system, serum cholesterol is elevated, and expression of cholesterol biosynthesis genes is elevated in the liver. (<italic>c</italic>) In symptomatic <italic>Mecp2</italic> null mice (8–10 weeks old), the brain is smaller due to lack of <italic>Mecp2</italic>. Cholesterol biosynthesis decreases drastically in the brain, likely due to feedback from elevated 24<italic>S</italic>-OHC. Owing to decreased synthesis, brain cholesterol remains high, but not as high as at younger ages (smaller red arrow). Serum cholesterol and/or triglycerides may also be elevated, depending upon genetic background. Triglycerides accumulate in the liver, and fatty liver disease develops, as indicated by pale liver.</p></caption><graphic xlink:href="rsob-8-170216-g4"></graphic></fig></p>
<p>Abnormalities in brain lipid homeostasis are associated with developmental disorders and diseases of ageing. Neimann–Pick type C patients accumulate cholesterol in the brain and peripheral tissues, and present with symptoms similar to RTT such as loss of acquired verbal skills and lack of motor coordination [<xref ref-type="bibr" rid="RSOB170216C164">164</xref>]. Patients with Smith–Lemli–Opitz syndrome develop microcephaly, cleft lip/palate, liver defects and autistic behaviours due to a deficiency in 7-dehydrocholesterol, allowing for the toxic build-up of cholesterol intermediates [<xref ref-type="bibr" rid="RSOB170216C165">165</xref>]. Furthermore, aberrant cholesterol homeostasis has been implicated in Fragile X syndrome [<xref ref-type="bibr" rid="RSOB170216C166">166</xref>], amyotrophic lateral sclerosis [<xref ref-type="bibr" rid="RSOB170216C167">167</xref>], Alzheimer's [<xref ref-type="bibr" rid="RSOB170216C168">168</xref>], Parkinson's [<xref ref-type="bibr" rid="RSOB170216C169">169</xref>] and Huntington's [<xref ref-type="bibr" rid="RSOB170216C170">170</xref>] diseases. However, lipid anomalies had never before been described in RTT and whether cholesterol played a primary role in the pathology of the disease was unknown.</p>
<p>Strikingly, Buchovecky <italic>et al.</italic> [<xref ref-type="bibr" rid="RSOB170216C156">156</xref>] found that cholesterol homeostasis is perturbed in the <italic>Mecp2</italic> null mouse brain. Pre-symptomatically, <italic>Mecp2</italic> null whole brain cholesterol is elevated, and <italic>Cyp46a1</italic> expression is increased 38% over wild-type levels, indicating a heightened need for cholesterol turnover in neurons [<xref ref-type="bibr" rid="RSOB170216C156">156</xref>] (<xref ref-type="fig" rid="RSOB170216F4">figure 4</xref><italic>b</italic>). Post-symptomatically, the overproduction of cholesterol decreases sterol synthesis <italic>in Mecp2</italic> null brains due to regulatory feedback [<xref ref-type="bibr" rid="RSOB170216C156">156</xref>,<xref ref-type="bibr" rid="RSOB170216C171">171</xref>] (<xref ref-type="fig" rid="RSOB170216F4">figure 4</xref><italic>c</italic>).</p>
<p>Notably, metabolic phenotypes differ in <italic>Mecp2</italic> null mice across genetic backgrounds. While both 129.<italic>Mecp2<sup>tm1.1Bird</sup></italic> mice and B6.<italic>Mecp2<sup>tm1.1Jae</sup></italic> mice show decreased sterol synthesis in the brain, elevated cholesterol and triglycerides in the serum and liver are observed only in 129.<italic>Mecp2<sup>tm1.1Bird</sup></italic> mice [<xref ref-type="bibr" rid="RSOB170216C156">156</xref>]. Additionally, CD1.<italic>Mecp2<sup>tm1.1Bird</sup></italic> mice have an increase in serum triglycerides with no corresponding change in serum cholesterol [<xref ref-type="bibr" rid="RSOB170216C125">125</xref>]. The C57BL/6 J inbred strain and the 129/Sv substrains manage peripheral cholesterol metabolism differently, presumably due to differences in the transport of cholesterol breakdown products [<xref ref-type="bibr" rid="RSOB170216C172">172</xref>]. Together, these data suggest that perturbed brain cholesterol synthesis is a common feature of <italic>Mecp2</italic> null mice; however, it is likely that genetic background contributes to the <italic>Mecp2</italic> null peripheral metabolic phenotype.</p>
<p>These differential findings in mice suggested that peripheral lipid markers would not be elevated in all patients. Consistently, only a subset of RTT patients exhibit increased serum cholesterol and/or triglycerides [<xref ref-type="bibr" rid="RSOB170216C15">15</xref>,<xref ref-type="bibr" rid="RSOB170216C16">16</xref>,<xref ref-type="bibr" rid="RSOB170216C173">173</xref>]. Outside of the CNS, sterols are the precursors of steroid hormones, bile acids and vitamin D. Interestingly, some RTT patients have bone abnormalities, severe gastrointestinal problems and biliary tract disorders [<xref ref-type="bibr" rid="RSOB170216C174">174</xref>–<xref ref-type="bibr" rid="RSOB170216C176">176</xref>]. As perturbations in lipid homeostasis may influence both neurological and non-neurological RTT symptoms, the measurement of lipid parameters may serve as a non-invasive and inexpensive biomarker to identify RTT patients who may benefit from treatments that target lipid metabolism.</p>
</sec>
<sec id="s7">
<label>7.</label>
<title>MeCP2 regulates lipid metabolism with NCoR1/SMRT-HDAC3</title>
<p>Notably, the NCoR1/SMRT corepressor complex is an important component in regulating the diurnal control of energy metabolism. During the fasting cycle, the NCoR1/SMRT-HDAC3 complex maximally occupies hepatocyte chromatin, repressing the expression of genes involved in lipid synthesis and sequestration. However, during the feeding cycle, it releases chromatin, allowing for expression of its targeted loci [<xref ref-type="bibr" rid="RSOB170216C177">177</xref>]. This binding oscillation governs the switch between lipid and glucose utilization in hepatocytes. Mice with a liver-specific deletion of <italic>Hdac3</italic> display an increased expression of <italic>de novo</italic> lipogenesis enzymes due to a constitutively active transcriptional environment, resulting in fatty liver disease and elevated serum cholesterol [<xref ref-type="bibr" rid="RSOB170216C178">178</xref>,<xref ref-type="bibr" rid="RSOB170216C179">179</xref>]. Overall, the NCoR1/SMRT-HDAC3 complex orchestrates lipogenesis, and its disruption leads to perturbed lipid homeostasis. Therefore, it was expected that loss of MeCP2<italic>,</italic> the functional bridge between NCoR1/SMRT-HDAC3 and DNA, would lead to transcriptional dysregulation of lipogenesis and metabolic perturbations in mice. In support of this, <italic>Sqle,</italic> the suppressor of RTT-like phenotypes in mice, is a target of HDAC3, and its transcription increases approximately 170-fold in response to <italic>Hdac3</italic> liver deletion [<xref ref-type="bibr" rid="RSOB170216C156">156</xref>,<xref ref-type="bibr" rid="RSOB170216C178">178</xref>].</p>
<p>Indeed, Kyle <italic>et al.</italic> [<xref ref-type="bibr" rid="RSOB170216C180">180</xref>] showed that <italic>Mecp2</italic> mutant mice develop severe dyslipidaemia due to aberrant transcription of lipogenesis enzymes in the liver, because MeCP2 interacts with the NCoR1/SMRT-HDAC3 complex to repress lipogenic gene transcription. Loss of MeCP2 decreases HDAC3 binding to DNA, resulting in hyperacetylated histones, and increases transcription of numerous lipid-regulating genes. Interestingly, liver-specific deletion of <italic>Mecp2</italic> (B6.<italic>Mecp2<sup>tm1Bird</sup>/</italic>Y;<italic>Alb-Cre</italic>) also results in an increase in lipogenic enzyme transcription [<xref ref-type="bibr" rid="RSOB170216C180">180</xref>]. Similar to <italic>Mecp2</italic> null mice and a liver-specific deletion of <italic>Hdac3</italic>, these mice develop dyslipidaemia, fatty liver and metabolic disease. These results support a hepatocyte-autonomous role for <italic>Mecp2</italic> in co-ordinating repression of enzymes of the cholesterol and triglyceride biosynthesis pathways and show that loss of <italic>Mecp2</italic> from the liver is sufficient to cause metabolic disease in mice. Notably, background strain is unlikely to influence MeCP2's role in regulating liver lipid synthesis as both 129.<italic>Mecp2<sup>tm1.1Bird</sup></italic> and B6.<italic>Mecp2<sup>tm1Bird</sup>/</italic>Y; <italic>Alb-Cre</italic> mice showed perturbed lipid metabolism.</p>
</sec>
<sec id="s8">
<label>8.</label>
<title>Cholesterol-lowering statin drugs may be repurposed to treat RTT</title>
<p>Considering that cholesterol metabolism is perturbed in <italic>Mecp2</italic> mice, it was possible that pharmacological treatment with cholesterol-lowering drugs (statins) would improve symptoms. The primary mechanism of action for statin drugs is to competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), a rate-limiting step in cholesterol biosynthesis [<xref ref-type="bibr" rid="RSOB170216C181">181</xref>], effectively reducing the endogenous production of cholesterol. Owing to the prominent role of cholesterol in cardiovascular disease, statins are medically prescribed to prevent atherosclerosis. However, statins are associated with other disease-improving side-effects, such as reducing inflammation [<xref ref-type="bibr" rid="RSOB170216C182">182</xref>,<xref ref-type="bibr" rid="RSOB170216C183">183</xref>], and negative side-effects, such as muscle weakness [<xref ref-type="bibr" rid="RSOB170216C184">184</xref>] and acute memory loss [<xref ref-type="bibr" rid="RSOB170216C185">185</xref>]. Owing to their relative safety, recent studies have explored how statin drugs can be repurposed to treat non-cardiovascular diseases including Fragile X syndrome and neurofibromatosis Type I [<xref ref-type="bibr" rid="RSOB170216C186">186</xref>,<xref ref-type="bibr" rid="RSOB170216C187">187</xref>].</p>
<p>Remarkably, treatment with either fluvastatin or lovastatin improves subjective health scores, motor performance (measured by rotarod and open field activity) and increases lifespan in 129.<italic>Mecp2<sup>tm1.1Bird</sup></italic> male and female mutant mice when compared with control mice receiving a vehicle [<xref ref-type="bibr" rid="RSOB170216C156">156</xref>]. Lovastatin is the more lipophilic of these statins, increasing the likelihood of crossing the BBB and entering the brain. Even so, treatment with either statin improves cholesterol homeostasis in the brains of <italic>Mecp2</italic> mutant mice, lowers serum cholesterol and ameliorates lipid accumulation in the liver. Interestingly, lovastatin does not have a strong therapeutic effect on B6.<italic>Mecp2<sup>tm1.1Bird</sup></italic> male mice, supporting the idea that elevated peripheral lipids may be a biomarker for those patients who may respond to statin drugs [<xref ref-type="bibr" rid="RSOB170216C188">188</xref>]. Nevertheless, these findings support the idea that lipid metabolism, a pathway that has many opportunities for drug or dietary intervention, could be exploited for symptom improvement in a subset of RTT patients [<xref ref-type="bibr" rid="RSOB170216C156">156</xref>]. Importantly, these findings led to a phase 2 clinical trial for the pharmacological treatment of RTT with lovastatin (NCT02563860).</p>
</sec>
<sec id="s9">
<label>9.</label>
<title>Implications for understanding and treating childhood neurological disorders</title>
<p>Rett syndrome remains a difficult disorder to understand and treat, largely because MeCP2 is central to the regulation of gene expression in many tissues and cell types. More than 60 years after the description of RTT as a metabolic disease of the nervous system, we have finally come to an understanding of some of the metabolic aspects of pathology (summarized in <xref ref-type="fig" rid="RSOB170216F5">figure 5</xref>). Despite this, metabolic parameters vary greatly within the RTT patient population and among different mouse strains indicating that genetic variation may play a large role in the penetrance of metabolic symptoms.
<fig id="RSOB170216F5" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Metabolic components of Rett syndrome. Common metabolic disturbances observed in RTT patients (blue squares), <italic>Mecp2-</italic>mutant mouse models (green triangles) that may be a feature of human disease, or in both human and mouse (pink circles). Note that metabolic parameters may vary within the patient population or among different mouse strains: for example, hyperammonaemia was found in a subset of patients, but was dropped as a diagnostic criterion because it was not common. Such findings suggest that genetic variation may play a big role in the penetrance of all but key diagnostic features.</p></caption><graphic xlink:href="rsob-8-170216-g5"></graphic></fig></p>
<p>In neurons, MeCP2 serves as a bridge between the NCoR1/SMRT-HDAC3 complex and DNA to facilitate transcriptional repression, and mutations that affect MeCP2 binding to the complex cause RTT. While both <italic>Ncor1</italic> and <italic>Hdac3</italic> null mice die as embryos, a neuron-specific deletion of <italic>Hdac3</italic> produces viable mice that gradually develop a phenotype very similar to that of <italic>Mecp2</italic> null mice including abnormal motor coordination, reduced sociability and cognitive defects [<xref ref-type="bibr" rid="RSOB170216C189">189</xref>]. These data suggest that at least a subset of RTT-like phenotypes in <italic>Mecp2</italic> mutant mice are caused by the loss of HDAC3 in neurons. Moreover, the role of the NCoR1/SMRT-HDAC3 in regulating lipogenesis in the <italic>Mecp2</italic> mouse liver raises interesting questions about the role of this complex in regulating lipids in the brain. Biochemistry studies have largely failed to find definitive gene regulatory targets, in part, because MeCP2 binds DNA at levels rivalling histone octamers [<xref ref-type="bibr" rid="RSOB170216C190">190</xref>]. Moreover, the brain is a complex organ with many different cell types in various stages of activity, making whole brain studies difficult to interpret. It is likely that at certain times and in specific cells, MeCP2 is required to anchor the NCoR1/SMRT-HDAC3 complex to DNA, regulating lipid production in some cells in the brain as in the liver.</p>
<p>As cholesterol synthesis is a resource-expensive process, current data suggest that newborn neurons must produce cholesterol in a cell-autonomous manner, but as they mature they outsource production to astrocytes (reviewed in [<xref ref-type="bibr" rid="RSOB170216C160">160</xref>,<xref ref-type="bibr" rid="RSOB170216C191">191</xref>]). Interestingly, wild-type neurons have abnormal dendritic morphology when co-cultured with MeCP2-deficient astrocytes, yet MeCP2-deficient neurons have normal dendritic morphology when co-cultured with wild-type astrocytes [<xref ref-type="bibr" rid="RSOB170216C192">192</xref>]. Moreover, deletion of MeCP2 from glial cells induces a RTT-like phenotype, and re-introducing MeCP2 to astrocytes of <italic>Mecp2</italic> null mice using GFAP-Cre improves symptoms and restores dendritic morphology [<xref ref-type="bibr" rid="RSOB170216C193">193</xref>,<xref ref-type="bibr" rid="RSOB170216C194">194</xref>]. These data could be explained by the hypothesis that at some point during development, cholesterol synthesis is reduced in a subset of neurons, and is provided instead by astrocytes; in the RTT brain, this downregulation does not occur, leading to lipid accumulation [<xref ref-type="bibr" rid="RSOB170216C160">160</xref>]. Certainly, this possibility may also explain the difference in timing of onset of symptoms in mice and humans, because the downregulation of cholesterol synthesis in neurons shortly precedes the onset of RTT-like symptoms in mice. New approaches provided by single-cell genomic technologies may provide definitive answers to this possibility.</p>
<p>Metabolic dysregulation in RTT and other diseases may impart substantial consequences on downstream systems. When one arm of metabolism is perturbed, it affects each connecting pathway, including glucose, lipid, amino acid, nitrogen and mitochondrial respiratory metabolism. Not surprisingly, both RTT patients and <italic>Mecp2</italic> mutant mice have abnormal responses to glucose tolerance tests, and mutant mice are also insulin-resistant [<xref ref-type="bibr" rid="RSOB170216C180">180</xref>,<xref ref-type="bibr" rid="RSOB170216C195">195</xref>]. Because <italic>Mecp2</italic> mice preferentially metabolize fat rather than glucose as their primary energy source, it is likely that other energy-sensing systems are affected. Specifically, energy metabolism affects the post-translational modification of proteins with O-linked <italic>N</italic>-acetylglucosamine (O-GlcNAc), a nutrient-driven epigenetic regulator [<xref ref-type="bibr" rid="RSOB170216C196">196</xref>,<xref ref-type="bibr" rid="RSOB170216C197">197</xref>]. The regulation of O-GlcNAc is required for many proteins involved in neurogenesis, and perturbation of O-GlcNAc protein modification has already been associated with many neurological diseases, including Alzheimer's [<xref ref-type="bibr" rid="RSOB170216C196">196</xref>,<xref ref-type="bibr" rid="RSOB170216C198">198</xref>]. Abnormal brain glucose-lipid homeostasis is also associated with oxidative stress in Alzheimer's [<xref ref-type="bibr" rid="RSOB170216C199">199</xref>]. RTT patients have increased oxidative burden and abnormal mitochondrial structure, while RTT animal models have defects in the mitochondrial respiratory chain [<xref ref-type="bibr" rid="RSOB170216C23">23</xref>,<xref ref-type="bibr" rid="RSOB170216C26">26</xref>,<xref ref-type="bibr" rid="RSOB170216C200">200</xref>–<xref ref-type="bibr" rid="RSOB170216C202">202</xref>] and oxidative changes in the brain [<xref ref-type="bibr" rid="RSOB170216C203">203</xref>]. Additionally, abnormal lipid metabolism is directly linked to inflammation [<xref ref-type="bibr" rid="RSOB170216C204">204</xref>], which is a component of pathology in both typical and atypical cases of RTT [<xref ref-type="bibr" rid="RSOB170216C205">205</xref>]. Notably, MeCP2 directly represses <italic>Irak1</italic> and downregulation of the NF-κβ pathway improves symptoms in <italic>Mecp2</italic> null mice [<xref ref-type="bibr" rid="RSOB170216C206">206</xref>].</p>
<p>The understanding of metabolic aspects of RTT pathology reveals potential therapeutic interventions. Statin drugs account for only one family of numerous metabolic modulators being developed to treat lipid accumulation or insulin resistance in Type II diabetes, which may be repurposed to treat RTT. Every year, new drug treatments are tested in <italic>Mecp2</italic> animal models that rescue different aspects of RTT phenotypes. For example, the treatment of <italic>Mecp2</italic> null mice with a protein-tyrosine phosphatase 1B (PTP1B) antagonist that was developed to treat Type II diabetes extended lifespan, decreased hindlimb clasping and improved motor performance [<xref ref-type="bibr" rid="RSOB170216C207">207</xref>]. Similarly, Trolox, a vitamin E derivative, normalized blood glucose levels, reduced oxidative stress and improved exploratory behaviour in <italic>Mecp2</italic> mice [<xref ref-type="bibr" rid="RSOB170216C208">208</xref>]. Additionally, insulin-like growth factor (IGF-1) partially rescued locomotor activity, respiratory function and heart rate in <italic>Mecp2</italic> mice [<xref ref-type="bibr" rid="RSOB170216C209">209</xref>,<xref ref-type="bibr" rid="RSOB170216C210">210</xref>]. In addition to statins, phase 2 clinical trials for RTT are in progress for a list of potential therapies including IGF-1 (NCT01777542), EPI-743 (NCT01822249), triheptanoin (NCT03059160) and NNZ-2566 (NCT01703533). However, despite this progress, no single treatment has yet fixed every phenotype in <italic>Mecp2</italic> mice or yet proved to effectively treat RTT symptoms.</p>
<p>While <italic>MeCP2</italic> has been largely studied in CNS development and maturation, some clinically significant aspects of RTT may arise independently of <italic>MECP2</italic> deficiency in the nervous system, and should be considered when planning any treatment strategy. Given the association between MeCP2 and HDAC3, non-specific HDAC inhibitors, commonly prescribed for seizure maintenance, should be approached cautiously as a treatment in RTT. Additionally, both RTT patients and <italic>Mecp2</italic> mutant mice present with metabolic syndrome [<xref ref-type="bibr" rid="RSOB170216C15">15</xref>,<xref ref-type="bibr" rid="RSOB170216C180">180</xref>], oxidative stress [<xref ref-type="bibr" rid="RSOB170216C27">27</xref>,<xref ref-type="bibr" rid="RSOB170216C29">29</xref>], cardiac defects [<xref ref-type="bibr" rid="RSOB170216C211">211</xref>,<xref ref-type="bibr" rid="RSOB170216C212">212</xref>], decreased bone density [<xref ref-type="bibr" rid="RSOB170216C174">174</xref>,<xref ref-type="bibr" rid="RSOB170216C213">213</xref>] and urological dysfunction [<xref ref-type="bibr" rid="RSOB170216C214">214</xref>,<xref ref-type="bibr" rid="RSOB170216C215">215</xref>]. As CNS-targeted gene therapy becomes a more realistic therapeutic approach, peripheral deficiency of MeCP2 must be considered more than ever as these symptoms are likely to persist following targeted genetic treatment to the brain.</p>
<p>Furthermore, mutations in members of the NCoR1/SMRT-HDAC3 complex should be examined for roles in other childhood neurological diseases. Already, mutations in other components of the complex, TBLR1 and TBL1, have been associated with autism, intellectual disability, Pierpont syndrome, a disorder characterized by developmental delay and abnormal fat distribution in the distal limbs, and West syndrome, a disorder with RTT-like features [<xref ref-type="bibr" rid="RSOB170216C216">216</xref>–<xref ref-type="bibr" rid="RSOB170216C219">219</xref>]. Notably, six of these mutations in TBLR1 mapped to the WD40 domain of the protein and disrupted MeCP2-binding [<xref ref-type="bibr" rid="RSOB170216C150">150</xref>]. Therefore, the transcriptional function of the NCoR1/SMRT complex could represent a shared mechanism for autism spectrum disorders and other neurological conditions. Comparing the transcriptome of mice with genetic deletions of <italic>Mecp2</italic> and members of the NCoR1/SMRT-HDAC3 complex may offer a comprehensive list of genes regulated by this interaction that can be studied to better understand disease pathology and exploited to develop potential treatments. Altogether, the progress in understanding the mechanistic basis for RTT pathology will continue to inform other neurological diseases and complex epigenetic mechanisms.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We thank all the girls with Rett syndrome and their families, who provide the motivation for our group to try to alleviate symptoms. We thank Julie Ruston and Stephanie Almeida for their critical comments on the manuscript.</p>
</ack>
<sec id="s10" sec-type="dataaccess">
<title>Data accessibility</title>
<p>This article has no additional data.</p>
</sec>
<sec id="s11" sec-type="aucontribute">
<title>Authors' contributions</title>
<p>S.M.K., N.V. and M.J.J. drafted and revised the manuscript. All authors gave final approval before submission.</p>
</sec>
<sec id="s12" sec-type="COI-statement">
<title>Competing interests</title>
<p>M.J.J. is a scientific founder of ArRETT Neurosciences, Inc., a company designed to provide treatments to Rett syndrome patients.</p>
</sec>
<sec id="s13" sec-type="funding">
<title>Funding</title>
<p>N.V. was supported by the Angel Ava Fund while writing this review.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="RSOB170216C1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rett</surname><given-names>A</given-names></name></person-group>
<year>1966</year>
<article-title>On a unusual brain atrophy syndrome in hyperammonemia in childhood</article-title>. <source/>Wien. Med. Wochenschr.
<volume>1946</volume>, <fpage>723</fpage>–<lpage>726</lpage>.</mixed-citation>
</ref>
<ref id="RSOB170216C2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagberg</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Aicardi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dias</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ramos</surname><given-names>O</given-names></name></person-group>
<year>1983</year>
<article-title>A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases</article-title>. <source/>Ann. Neurol.
<volume>14</volume>, <fpage>471</fpage>–<lpage>479</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ana.410140412">doi:10.1002/ana.410140412</ext-link>)<pub-id pub-id-type="pmid">6638958</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burd</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Randall</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Martsolf</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Kerbeshian</surname><given-names>J</given-names></name></person-group>
<year>1991</year>
<article-title>Rett syndrome symptomatology of institutionalized adults with mental retardation: comparison of males and females</article-title>. <source/>Am. J. Ment. Retard.
<volume>95</volume>, <fpage>596</fpage>–<lpage>601</lpage>.<pub-id pub-id-type="pmid">2043352</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagberg</surname><given-names>B</given-names></name></person-group>
<year>2002</year>
<article-title>Clinical manifestations and stages of Rett syndrome</article-title>. <source/>Ment. Retard. Dev. Disabil. Res. Rev.
<volume>8</volume>, <fpage>61</fpage>–<lpage>65</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mrdd.10020">doi:10.1002/mrdd.10020</ext-link>)<pub-id pub-id-type="pmid">12112728</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagberg</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Witt-Engerström</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Opitz</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Reynolds</surname><given-names>JF</given-names></name></person-group>
<year>1986</year>
<article-title>Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence</article-title>. <source/>Am. J. Med. Genet.
<volume>25</volume>, <fpage>47</fpage>–<lpage>59</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajmg.1320250506">doi:10.1002/ajmg.1320250506</ext-link>)<pub-id pub-id-type="pmid">3799723</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neul</surname><given-names>JL</given-names></name><etal>et al.</etal></person-group>
<year>2010</year>
<article-title>Rett syndrome: revised diagnostic criteria and nomenclature</article-title>. <source/>Ann. Neurol.
<volume>68</volume>, <fpage>944</fpage>–<lpage>950</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ana.22124">doi:10.1002/ana.22124</ext-link>)<pub-id pub-id-type="pmid">21154482</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haas</surname><given-names>RH</given-names></name></person-group>
<year>1988</year>
<article-title>The history and challenge of Rett syndrome</article-title>. <source/>J. Child Neurol.
<volume>3</volume>, <fpage>S3</fpage>–<lpage>S5</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/088307388800300102">doi:10.1177/088307388800300102</ext-link>)<pub-id pub-id-type="pmid">3058785</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Townend</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Marschik</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Smeets</surname><given-names>E</given-names></name>, <name name-style="western"><surname>van de Berg</surname><given-names>R</given-names></name>, <name name-style="western"><surname>van den Berg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Curfs</surname><given-names>LMG</given-names></name></person-group>
<year>2016</year>
<article-title>Eye gaze technology as a form of augmentative and alternative communication for individuals with Rett syndrome: experiences of families in the Netherlands</article-title>. <source/>J. Dev. Phys. Disabil.
<volume>28</volume>, <fpage>101</fpage>–<lpage>112</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10882-015-9455-z">doi:10.1007/s10882-015-9455-z</ext-link>)<pub-id pub-id-type="pmid">27069348</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jellinger</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Seitelberger</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Opitz</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Reynolds</surname><given-names>JF</given-names></name></person-group>
<year>1986</year>
<article-title>Neuropathology of Rett syndrome</article-title>. <source/>Am. J. Med. Genet.
<volume>25</volume>, <fpage>259</fpage>–<lpage>288</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajmg.1320250528">doi:10.1002/ajmg.1320250528</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jellinger</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Percy</surname><given-names>AK</given-names></name></person-group>
<year>1988</year>
<article-title>Neuropathology of Rett syndrome</article-title>. <source/>Acta Neuropathol.. <volume>76</volume>, <fpage>142</fpage>–<lpage>158</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/BF00688098">doi:10.1007/BF00688098</ext-link>)<pub-id pub-id-type="pmid">2900587</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>DD</given-names></name></person-group>
<year>1992</year>
<article-title>The neuropathology of the Rett syndrome</article-title>. <source/>Brain Dev.
<volume>14</volume>, <fpage>S89</fpage>–<lpage>S98</lpage>.<pub-id pub-id-type="pmid">1626639</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Moser</surname><given-names>HW</given-names></name></person-group>
<year>2000</year>
<article-title>Dendritic anomalies in disorders associated with mental retardation</article-title>. <source/>Cereb. Cortex
<volume>10</volume>, <fpage>981</fpage>–<lpage>991</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cercor/10.10.981">doi:10.1093/cercor/10.10.981</ext-link>)<pub-id pub-id-type="pmid">11007549</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taneja</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ogier</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brooks-Harris</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schmid</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Katz</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>SB</given-names></name></person-group>
<year>2009</year>
<article-title>Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome</article-title>. <source/>J. Neurosci.
<volume>29</volume>, <fpage>12 187</fpage>–<lpage>12 195</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1523/JNEUROSCI.3156-09.2009">doi:10.1523/JNEUROSCI.3156-09.2009</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoghbi</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Milstien</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Butler</surname><given-names>IJ</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>EOB</given-names></name>, <name name-style="western"><surname>Kaufman</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Glaze</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Percy</surname><given-names>AK</given-names></name></person-group>
<year>1989</year>
<article-title>Cerebrospinal fluid biogenic amines and biopterin in rett syndrome</article-title>. <source/>Ann. Neurol.
<volume>25</volume>, <fpage>56</fpage>–<lpage>60</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ana.410250109">doi:10.1002/ana.410250109</ext-link>)<pub-id pub-id-type="pmid">2913929</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Justice</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Buchovecky</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Kyle</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Djukic</surname><given-names>A</given-names></name></person-group>
<year>2013</year>
<article-title>A role for metabolism in Rett syndrome pathogenesis: new clinical findings and potential treatment targets</article-title>. <source/>Rare Dis.
<volume>1</volume>, <fpage>e27265</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4161/rdis.27265">doi:10.4161/rdis.27265</ext-link>)<pub-id pub-id-type="pmid">25003017</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segatto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Trapani</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Di Tunno</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Sticozzi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Valacchi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hayek</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pallottini</surname><given-names>V</given-names></name></person-group>
<year>2014</year>
<article-title>Cholesterol metabolism is altered in Rett syndrome: a study on plasma and primary cultured fibroblasts derived from patients</article-title>. <source/>PLoS ONE
<volume>9</volume>, <fpage>e104834</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0104834">doi:10.1371/journal.pone.0104834</ext-link>)<pub-id pub-id-type="pmid">25118178</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acampa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Guideri</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hayek</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Blardi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>De Lalla</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zappella</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Auteri</surname><given-names>A</given-names></name></person-group>
<year>2008</year>
<article-title>Sympathetic overactivity and plasma leptin levels in Rett syndrome</article-title>. <source/>Neurosci. Lett.
<volume>432</volume>, <fpage>69</fpage>–<lpage>72</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neulet.2007.12.030">doi:10.1016/j.neulet.2007.12.030</ext-link>)<pub-id pub-id-type="pmid">18226448</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blardi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>De Lalla</surname><given-names>A</given-names></name>, <name name-style="western"><surname>D'Ambrogio</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Vonella</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ceccatelli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Auteri</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hayek</surname><given-names>J</given-names></name></person-group>
<year>2009</year>
<article-title>Long-term plasma levels of leptin and adiponectin in Rett syndrome</article-title>. <source/>Clin. Endocrinol.
<volume>70</volume>, <fpage>706</fpage>–<lpage>709</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2265.2008.03386.x">doi:10.1111/j.1365-2265.2008.03386.x</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freilinger</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Prevalence, clinical investigation, and management of gallbladder disease in Rett syndrome</article-title>. <source/>Dev. Med. Child Neurol.
<volume>56</volume>, <fpage>756</fpage>–<lpage>762</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/dmcn.12358">doi:10.1111/dmcn.12358</ext-link>)<pub-id pub-id-type="pmid">24528171</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuishi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Urabe</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Percy</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Komori</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yamashita</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Schultz</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Ohtani</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kuriya</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kato</surname><given-names>H</given-names></name></person-group>
<year>1994</year>
<article-title>Abnormal carbohydrate metabolism in cerebrospinal fluid in Rett syndrome</article-title>. <source/>J. Child Neurol.
<volume>9</volume>, <fpage>26</fpage>–<lpage>30</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/088307389400900105">doi:10.1177/088307389400900105</ext-link>)<pub-id pub-id-type="pmid">8151077</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanefeld</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Christen</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Holzbach</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Kruse</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Frahm</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hanicke</surname><given-names>W</given-names></name></person-group>
<year>1995</year>
<article-title>Cerebral proton magnetic resonance spectroscopy in Rett syndrome</article-title>. <source/>Neuropediatrics
<volume>26</volume>, <fpage>126</fpage>–<lpage>127</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1055/s-2007-979742">doi:10.1055/s-2007-979742</ext-link>)<pub-id pub-id-type="pmid">7566451</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horska</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Naidu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Herskovits</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>PY</given-names></name>, <name name-style="western"><surname>Kaufmann</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Barker</surname><given-names>PB</given-names></name></person-group>
<year>2000</year>
<article-title>Quantitative 1H MR spectroscopic imaging in early Rett syndrome</article-title>. <source/>Neurology
<volume>54</volume>, <fpage>715</fpage>–<lpage>722</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/WNL.54.3.715">doi:10.1212/WNL.54.3.715</ext-link>)<pub-id pub-id-type="pmid">10680809</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eeg-Olofsson</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Al-Zuhair</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Teebi</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Al-Essa</surname><given-names>MM</given-names></name></person-group>
<year>1988</year>
<article-title>Abnormal mitochondria in the Rett syndrome</article-title>. <source/>Brain Dev.. <volume>10</volume>, <fpage>260</fpage>–<lpage>262</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0387-7604(88)80010-X">doi:10.1016/S0387-7604(88)80010-X</ext-link>)<pub-id pub-id-type="pmid">3218707</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eeg-Olofsson</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Al-Zuhair</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Teebi</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Daoud</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Zaki</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Besisso</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Al-Essa</surname><given-names>MM</given-names></name></person-group>
<year>1990</year>
<article-title>Rett syndrome: a mitochondrial disease?</article-title>. <source/>J. Child Neurol.
<volume>5</volume>, <fpage>210</fpage>–<lpage>214</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/088307389000500311">doi:10.1177/088307389000500311</ext-link>)<pub-id pub-id-type="pmid">2168910</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakai</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kameda</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ishikawa</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Miyamoto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nagaoka</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Okabe</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Minami</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tachi</surname><given-names>N</given-names></name></person-group>
<year>1990</year>
<article-title>Rett syndrome: findings suggesting axonopathy and mitochondrial abnormalities</article-title>. <source/>Pediatr. Neurol.
<volume>6</volume>, <fpage>339</fpage>–<lpage>343</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0887-8994(90)90028-Y">doi:10.1016/0887-8994(90)90028-Y</ext-link>)<pub-id pub-id-type="pmid">2242177</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardaioli</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Dotti</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Hayek</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zappella</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Federico</surname><given-names>A</given-names></name></person-group>
<year>1999</year>
<article-title>Studies on mitochondrial pathogenesis of Rett syndrome: ultrastructural data from skin and muscle biopsies and mutational analysis at mtDNA nucleotides 10463 and 2835</article-title>. <source/>J. Submicrosc. Cytol. Pathol.
<volume>31</volume>, <fpage>301</fpage>–<lpage>304</lpage>.<pub-id pub-id-type="pmid">10457616</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haas</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Nasirian</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hua</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Nakano</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hennessy</surname><given-names>M</given-names></name></person-group>
<year>1995</year>
<article-title>Oxidative metabolism in Rett syndrome. 2. Biochemical and molecular studies</article-title>. <source/>Neuropediatrics
<volume>26</volume>, <fpage>95</fpage>–<lpage>99</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1055/s-2007-979735">doi:10.1055/s-2007-979735</ext-link>)<pub-id pub-id-type="pmid">7566465</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sierra</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vilaseca</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Brandi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Artuch</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mira</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nieto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pineda</surname><given-names>M</given-names></name></person-group>
<year>2001</year>
<article-title>Oxidative stress in Rett syndrome</article-title>. <source/>Brain Dev.
<volume>23</volume>(<issue>Suppl 1</issue>), <fpage>S236</fpage>–<lpage>S239</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0387-7604(01)00369-2">doi:10.1016/S0387-7604(01)00369-2</ext-link>)<pub-id pub-id-type="pmid">11738881</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Felice</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<year>2009</year>
<article-title>Systemic oxidative stress in classic Rett syndrome</article-title>. <source/>Free Radic. Biol. Med.
<volume>47</volume>, <fpage>440</fpage>–<lpage>448</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.freeradbiomed.2009.05.016">doi:10.1016/j.freeradbiomed.2009.05.016</ext-link>)<pub-id pub-id-type="pmid">19464363</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leoncini</surname><given-names>S</given-names></name>, <name name-style="western"><surname>De Felice</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Signorini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pecorelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Durand</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Valacchi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ciccoli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hayek</surname><given-names>J</given-names></name></person-group>
<year>2011</year>
<article-title>Oxidative stress in Rett syndrome: natural history, genotype, and variants</article-title>. <source/>Redox Rep.
<volume>16</volume>, <fpage>145</fpage>–<lpage>153</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1179/1351000211Y.0000000004">doi:10.1179/1351000211Y.0000000004</ext-link>)<pub-id pub-id-type="pmid">21888765</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shulyakova</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Andreazza</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Mills</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Eubanks</surname><given-names>JH</given-names></name></person-group>
<year>2017</year>
<article-title>Mitochondrial dysfunction in the pathogenesis of Rett syndrome: implications for mitochondria-targeted therapies</article-title>. <source/>Front. Cell. Neurosci.
<volume>11</volume>, <fpage>58</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fncel.2017.00058">doi:10.3389/fncel.2017.00058</ext-link>)<pub-id pub-id-type="pmid">28352216</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Prescott</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Doyle</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kearney</surname><given-names>DL</given-names></name></person-group>
<year>1997</year>
<article-title>Rett syndrome: analysis of deaths in the British survey</article-title>. <source/>Eur. Child Adolesc. Psychiat.
<volume>6</volume>(<issue>Suppl 1</issue>), <fpage>71</fpage>–<lpage>74</lpage>.</mixed-citation>
</ref>
<ref id="RSOB170216C33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laurvick</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>de Klerk</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bower</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Christodoulou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ravine</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ellaway</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Williamson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>H</given-names></name></person-group>
<year>2006</year>
<article-title>Rett syndrome in Australia: a review of the epidemiology</article-title>. <source/>J. Pediatr.
<volume>148</volume>, <fpage>347</fpage>–<lpage>352</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jpeds.2005.10.037">doi:10.1016/j.jpeds.2005.10.037</ext-link>)<pub-id pub-id-type="pmid">16615965</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Jacoby</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Downs</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>H</given-names></name></person-group>
<year>2014</year>
<article-title>Twenty years of surveillance in Rett syndrome: what does this tell us?</article-title>
<source/>Orphanet J. Rare Dis.
<volume>9</volume>, <fpage>87</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1750-1172-9-87">doi:10.1186/1750-1172-9-87</ext-link>)<pub-id pub-id-type="pmid">24942262</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sirianni</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Naidu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pereira</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pillotto</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Hoffman</surname><given-names>EP</given-names></name></person-group>
<year>1998</year>
<article-title>Rett syndrome: confirmation of X-linked dominant inheritance, and localization of the gene to Xq28</article-title>. <source/>Am. J. Hum. Genet.
<volume>63</volume>, <fpage>1552</fpage>–<lpage>1558</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/302105">doi:10.1086/302105</ext-link>)<pub-id pub-id-type="pmid">9792883</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amir</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Van den Veyver</surname><given-names>IB</given-names></name>, <name name-style="western"><surname>Wan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tran</surname><given-names>CQ</given-names></name>, <name name-style="western"><surname>Francke</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group>
<year>1999</year>
<article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl- CpG-binding protein 2</article-title>. <source/>Nat. Genet.
<volume>23</volume>, <fpage>185</fpage>–<lpage>188</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/13810">doi:10.1038/13810</ext-link>)<pub-id pub-id-type="pmid">10508514</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>1999</year>
<article-title>Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots</article-title>. <source/>Am. J. Hum. Genet.
<volume>65</volume>, <fpage>1520</fpage>–<lpage>1529</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/302690">doi:10.1086/302690</ext-link>)<pub-id pub-id-type="pmid">10577905</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neul</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Barrish</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lane</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Caeg</surname><given-names>EB</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>EO</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Percy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Glaze</surname><given-names>DG</given-names></name></person-group>
<year>2008</year>
<article-title>Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome</article-title>. <source/>Neurology
<volume>70</volume>, <fpage>1313</fpage>–<lpage>1321</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/01.wnl.0000291011.54508.aa">doi:10.1212/01.wnl.0000291011.54508.aa</ext-link>)<pub-id pub-id-type="pmid">18337588</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weaving</surname><given-names>LS</given-names></name><etal>et al.</etal></person-group>
<year>2004</year>
<article-title>Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation</article-title>. <source/>Am. J. Hum. Genet.
<volume>75</volume>, <fpage>1079</fpage>–<lpage>1093</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/426462">doi:10.1086/426462</ext-link>)<pub-id pub-id-type="pmid">15492925</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<year>2004</year>
<article-title>Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation</article-title>. <source/>Am. J. Hum. Genet.
<volume>75</volume>, <fpage>1149</fpage>–<lpage>1154</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/426460">doi:10.1086/426460</ext-link>)<pub-id pub-id-type="pmid">15499549</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scala</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<year>2005</year>
<article-title>CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms</article-title>. <source/>J. Med. Genet.
<volume>42</volume>, <fpage>103</fpage>–<lpage>107</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/jmg.2004.026237">doi:10.1136/jmg.2004.026237</ext-link>)<pub-id pub-id-type="pmid">15689447</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sartori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Di Rosa</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Polli</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bettella</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Tricomi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Tortorella</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Murgia</surname><given-names>A</given-names></name></person-group>
<year>2009</year>
<article-title>A novel <italic>CDKL5</italic> mutation in a 47,XXY boy with the early-onset seizure variant of Rett syndrome</article-title>. <source/>Am. J. Med. Genet. Part A
<volume>149</volume>, <fpage>232</fpage>–<lpage>236</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajmg.a.32606">doi:10.1002/ajmg.a.32606</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fehr</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy</article-title>. <source/>Eur. J. Hum. Genet.
<volume>21</volume>, <fpage>266</fpage>–<lpage>273</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ejhg.2012.156">doi:10.1038/ejhg.2012.156</ext-link>)<pub-id pub-id-type="pmid">22872100</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrini</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Parrini</surname><given-names>E</given-names></name></person-group>
<year>2012</year>
<article-title>Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies</article-title>. <source/>Epilepsia
<volume>53</volume>, <fpage>2067</fpage>–<lpage>2078</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1528-1167.2012.03656.x">doi:10.1111/j.1528-1167.2012.03656.x</ext-link>)<pub-id pub-id-type="pmid">22998673</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ariani</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>
<year>2008</year>
<article-title>FOXG1 is responsible for the congenital variant of Rett syndrome</article-title>. <source/>Am. J. Hum. Genet.
<volume>83</volume>, <fpage>89</fpage>–<lpage>93</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ajhg.2008.05.015">doi:10.1016/j.ajhg.2008.05.015</ext-link>)<pub-id pub-id-type="pmid">18571142</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mencarelli</surname><given-names>MA</given-names></name><etal>et al.</etal></person-group>
<year>2010</year>
<article-title>Novel FOXG1 mutations associated with the congenital variant of Rett syndrome</article-title>. <source/>J. Med. Genet.
<volume>47</volume>, <fpage>49</fpage>–<lpage>53</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/jmg.2009.067884">doi:10.1136/jmg.2009.067884</ext-link>)<pub-id pub-id-type="pmid">19578037</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philippe</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Amsallem</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Francannet</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lambert</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Saunier</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Verneau</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Jonveaux</surname><given-names>P</given-names></name></person-group>
<year>2010</year>
<article-title>Phenotypic variability in Rett syndrome associated with FOXG1 mutations in females</article-title>. <source/>J. Med. Genet.
<volume>47</volume>, <fpage>59</fpage>–<lpage>65</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/jmg.2009.067355">doi:10.1136/jmg.2009.067355</ext-link>)<pub-id pub-id-type="pmid">19564653</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung Jae</surname><given-names>LS</given-names></name><etal>et al.</etal></person-group>
<year>2001</year>
<article-title>Spectrum of MECP2 mutations in Rett syndrome</article-title>. <source/>Brain Dev.
<volume>23</volume>(<issue>Suppl. 1</issue>), <fpage>S138</fpage>–<lpage>S143</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0387-7604(01)00339-4">doi:10.1016/S0387-7604(01)00339-4</ext-link>)<pub-id pub-id-type="pmid">11738860</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zappella</surname><given-names>M</given-names></name></person-group>
<year>1992</year>
<article-title>The Rett girls with preserved speech</article-title>. <source/>Brain Dev.
<volume>14</volume>, <fpage>98</fpage>–<lpage>101</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0387-7604(12)80094-5">doi:10.1016/S0387-7604(12)80094-5</ext-link>)<pub-id pub-id-type="pmid">1621933</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koelsch</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Webb</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jeffries</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dozmorov</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Frank</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Guthridge</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>James</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Wren</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Sawalha</surname><given-names>AH</given-names></name></person-group>
<year>2013</year>
<article-title>Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse</article-title>. <source/>J. Autoimmun.
<volume>41</volume>, <fpage>168</fpage>–<lpage>174</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jaut.2012.12.012">doi:10.1016/j.jaut.2012.12.012</ext-link>)<pub-id pub-id-type="pmid">23428850</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schönewolf-Greulich</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>The <italic>MECP2</italic> variant c.925C&gt;T (p.Arg309Trp) causes intellectual disability in both males and females without classic features of Rett syndrome</article-title>. <source/>Clin. Genet.
<volume>89</volume>, <fpage>733</fpage>–<lpage>738</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/cge.12769">doi:10.1111/cge.12769</ext-link>)<pub-id pub-id-type="pmid">26936630</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tate</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Skarnes</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>1996</year>
<article-title>The methyl-CpG binding protein MeCP2 is essential for embryonic development in the mouse</article-title>. <source/>Nat. Genet.
<volume>12</volume>, <fpage>205</fpage>–<lpage>208</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng0296-205">doi:10.1038/ng0296-205</ext-link>)<pub-id pub-id-type="pmid">8563762</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>JD</given-names></name><etal>et al.</etal></person-group>
<year>1992</year>
<article-title>Purification, sequence, and cellular localization of a novel chromosomal protein that binds to Methylated DNA</article-title>. <source/>Cell
<volume>69</volume>, <fpage>905</fpage>–<lpage>914</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0092-8674(92)90610-O">doi:10.1016/0092-8674(92)90610-O</ext-link>)<pub-id pub-id-type="pmid">1606614</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>DRS</given-names></name>, <name name-style="western"><surname>Matarazzo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Palmer</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Jeon</surname><given-names>O-H</given-names></name>, <name name-style="western"><surname>Pevsner</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ronnett</surname><given-names>GV</given-names></name></person-group>
<year>2003</year>
<article-title>Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis</article-title>. <source/>Mol. Cell. Neurosci.
<volume>22</volume>, <fpage>417</fpage>–<lpage>429</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1044-7431(03)00026-5">doi:10.1016/S1044-7431(03)00026-5</ext-link>)<pub-id pub-id-type="pmid">12727440</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>BP</given-names></name>, <name name-style="western"><surname>Jugloff</surname><given-names>DGM</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Logan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Eubanks</surname><given-names>JH</given-names></name></person-group>
<year>2003</year>
<article-title>The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cells</article-title>. <source/>J. Neurobiol.
<volume>55</volume>, <fpage>86</fpage>–<lpage>96</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/neu.10201">doi:10.1002/neu.10201</ext-link>)<pub-id pub-id-type="pmid">12605461</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samaco</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Nagarajan</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Braunschweig</surname><given-names>D</given-names></name>, <name name-style="western"><surname>LaSalle</surname><given-names>JM</given-names></name></person-group>
<year>2004</year>
<article-title>Multiple pathways regulate MeCP2 expression in normal brain development and exhibit defects in autism-spectrum disorders</article-title>. <source/>Hum. Mol. Genet.
<volume>13</volume>, <fpage>629</fpage>–<lpage>639</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddh063">doi:10.1093/hmg/ddh063</ext-link>)<pub-id pub-id-type="pmid">14734626</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Macklis</surname><given-names>JD</given-names></name></person-group>
<year>2005</year>
<article-title>Dissecting MECP2 function in the central nervous system</article-title>. <source/>J. Child Neurol.
<volume>20</volume>, <fpage>753</fpage>–<lpage>759</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/08830738050200091001">doi:10.1177/08830738050200091001</ext-link>)<pub-id pub-id-type="pmid">16225831</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kent</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Sugnet</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Furey</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Roskin</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Pringle</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Zahler</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Haussler</surname><given-names>AD</given-names></name></person-group>
<year>2002</year>
<article-title>The Human Genome Browser at UCSC</article-title>. <source/>Genome Res.. <volume>12</volume>, <fpage>996</fpage>–<lpage>1006</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gr.229102">doi:10.1101/gr.229102</ext-link>)<pub-id pub-id-type="pmid">12045153</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mnatzakanian</surname><given-names>GN</given-names></name><etal>et al.</etal></person-group>
<year>2004</year>
<article-title>A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome</article-title>. <source/>Nat. Genet.
<volume>36</volume>, <fpage>339</fpage>–<lpage>341</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng1327">doi:10.1038/ng1327</ext-link>)<pub-id pub-id-type="pmid">15034579</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kriaucionis</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>2004</year>
<article-title>The major form of MeCP2 has a novel N-terminus generated by alternative splicing</article-title>. <source/>Nucleic Acids Res.
<volume>32</volume>, <fpage>1818</fpage>–<lpage>1823</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkh349">doi:10.1093/nar/gkh349</ext-link>)<pub-id pub-id-type="pmid">15034150</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olson</surname><given-names>CO</given-names></name>, <name name-style="western"><surname>Zachariah</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Ezeonwuka</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Liyanage</surname><given-names>VRB</given-names></name>, <name name-style="western"><surname>Rastegar</surname><given-names>M</given-names></name></person-group>
<year>2014</year>
<article-title>Brain region-specific expression of MeCP2 isoforms correlates with DNA methylation within Mecp2 regulatory elements</article-title>. <source/>PLoS ONE
<volume>9</volume>, <fpage>e90645</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0090645">doi:10.1371/journal.pone.0090645</ext-link>)<pub-id pub-id-type="pmid">24594659</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelka</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Watson</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Christodoulou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tam</surname><given-names>PPL</given-names></name></person-group>
<year>2005</year>
<article-title>Distinct expression profiles of Mecp2 transcripts with different lengths of 3′UTR in the brain and visceral organs during mouse development</article-title>. <source/>Genomics
<volume>85</volume>, <fpage>441</fpage>–<lpage>452</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ygeno.2004.12.002">doi:10.1016/j.ygeno.2004.12.002</ext-link>)<pub-id pub-id-type="pmid">15780747</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coy</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Sedlacek</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Bächner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Delius</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Poustka</surname><given-names>A</given-names></name></person-group>
<year>1999</year>
<article-title>A complex pattern of evolutionary conservation and alternative polyadenylation within the long 3′ untranslated region of the methyl-CpG-binding protein 2 gene (MeCP2) suggests a regulatory role in gene expression</article-title>. <source/>Hum. Mol. Genet.
<volume>8</volume>, <fpage>1253</fpage>–<lpage>1262</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/8.7.1253">doi:10.1093/hmg/8.7.1253</ext-link>)<pub-id pub-id-type="pmid">10369871</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Esposito</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Quaderi</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Ciccodicola</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bruni</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Esposito</surname><given-names>T</given-names></name>, <name name-style="western"><surname>D'Urso</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>SDM</given-names></name></person-group>
<year>1996</year>
<article-title>Isolation, physical mapping, and Northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2</article-title>. <source/>Mamm. Genome
<volume>7</volume>, <fpage>533</fpage>–<lpage>535</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s003359900157">doi:10.1007/s003359900157</ext-link>)<pub-id pub-id-type="pmid">8672133</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGowan</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pang</surname><given-names>ZP</given-names></name></person-group>
<year>2015</year>
<article-title>Regulatory functions and pathological relevance of the <italic>MECP2</italic> 3′UTR in the central nervous system</article-title>. <source/>Cell Regen.
<volume>4</volume>, <fpage>9</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13619-015-0023-x">doi:10.1186/s13619-015-0023-x</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Meehan</surname><given-names>RR</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>1993</year>
<article-title>Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2</article-title>. <source/>Nucleic Acids Res.
<volume>21</volume>, <fpage>4886</fpage>–<lpage>4892</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/21.21.4886">doi:10.1093/nar/21.21.4886</ext-link>)<pub-id pub-id-type="pmid">8177735</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C67">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagger</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>MeCP2 recognizes cytosine methylated tri-nucleotide and di-nucleotide sequences to tune transcription in the mammalian brain</article-title>. <source/>PLoS Genet.
<volume>13</volume>, <fpage>e1006793</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pgen.1006793">doi:10.1371/journal.pgen.1006793</ext-link>)<pub-id pub-id-type="pmid">28498846</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Campoy</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>1997</year>
<article-title>MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin</article-title>. <source/>Cell
<volume>88</volume>, <fpage>471</fpage>–<lpage>481</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0092-8674(00)81887-5">doi:10.1016/S0092-8674(00)81887-5</ext-link>)<pub-id pub-id-type="pmid">9038338</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C69">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Tate</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>1996</year>
<article-title>DNA methylation specifies chromosomal localization of MeCP2</article-title>. <source/>Mol. Cell. Biol.
<volume>16</volume>, <fpage>414</fpage>–<lpage>421</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/MCB.16.1.414">doi:10.1128/MCB.16.1.414</ext-link>)<pub-id pub-id-type="pmid">8524323</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyst</surname><given-names>MJ</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor</article-title>. <source/>Nat. Neurosci.
<volume>16</volume>, <fpage>898</fpage>–<lpage>902</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nn.3434">doi:10.1038/nn.3434</ext-link>)<pub-id pub-id-type="pmid">23770565</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebert</surname><given-names>DH</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR</article-title>. <source/>Nature
<volume>499</volume>, <fpage>341</fpage>–<lpage>345</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature12348">doi:10.1038/nature12348</ext-link>)<pub-id pub-id-type="pmid">23770587</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandler</surname><given-names>SPSP</given-names></name>, <name name-style="western"><surname>Guschin</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Landsberger</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Wolffe</surname><given-names>APAP</given-names></name></person-group>
<year>1999</year>
<article-title>The methyl-CpG binding transcriptional repressor MeCP2 stably associates with nucleosomal DNA</article-title>. <source/>Biochemistry
<volume>38</volume>, <fpage>7008</fpage>–<lpage>7018</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/bi990224y">doi:10.1021/bi990224y</ext-link>)<pub-id pub-id-type="pmid">10353812</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bird</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tweedie</surname><given-names>S</given-names></name></person-group>
<year>1995</year>
<article-title>Transcriptional noise and the evolution of gene number</article-title>. <source/>Phil. Trans. R. Soc. B.
<volume>349</volume>, <fpage>249</fpage>–<lpage>253</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1098/rstb.1995.0109">doi:10.1098/rstb.1995.0109</ext-link>)<pub-id pub-id-type="pmid">8577835</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tweedie</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Charlton</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>1997</year>
<article-title>Methylation of genomes and genes at the invertebrate-vertebrate boundary</article-title>. <source/>Mol. Cell. Biol.
<volume>17</volume>, <fpage>1469</fpage>–<lpage>1475</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/MCB.17.3.1469">doi:10.1128/MCB.17.3.1469</ext-link>)<pub-id pub-id-type="pmid">9032274</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stein</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Razin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cedar</surname><given-names>H</given-names></name></person-group>
<year>1982</year>
<article-title><italic>In vitro</italic> methylation of the hamster adenine phosphoribosyltransferase gene inhibits its expression in mouse L cells</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>79</volume>, <fpage>3418</fpage>–<lpage>3422</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.79.11.3418">doi:10.1073/pnas.79.11.3418</ext-link>)<pub-id pub-id-type="pmid">6954487</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>H-HH</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Laherty</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Eisenman</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>1998</year>
<article-title>Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex</article-title>. <source/>Nature
<volume>393</volume>, <fpage>386</fpage>–<lpage>389</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/30764">doi:10.1038/30764</ext-link>)<pub-id pub-id-type="pmid">9620804</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chahrour</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>SYY</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>STCTC</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>HYY</given-names></name></person-group>
<year>2008</year>
<article-title>MeCP2, a key contributor to neurological disease, activates and represses transcription</article-title>. <source/>Science
<volume>320</volume>, <fpage>1224</fpage>–<lpage>1229</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1153252">doi:10.1126/science.1153252</ext-link>)<pub-id pub-id-type="pmid">18511691</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Georgel</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Horowitz-Scherer</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Adkins</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Woodcock</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Wade</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>JC</given-names></name></person-group>
<year>2003</year>
<article-title>Chromatin compaction by human MeCP2: asssembly of novel secondary chromatin structures in the absence of DNA methylation</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>32 181</fpage>–<lpage>32 188</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M305308200">doi:10.1074/jbc.M305308200</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wilkins</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lichtarge</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group>
<year>2013</year>
<article-title>An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders</article-title>. <source/>Cell
<volume>152</volume>, <fpage>984</fpage>–<lpage>996</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2013.01.038">doi:10.1016/j.cell.2013.01.038</ext-link>)<pub-id pub-id-type="pmid">23452848</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>Misregulation of alternative splicing in a mouse model of Rett syndrome</article-title>. <source/>PLoS Genet.
<volume>12</volume>, <fpage>e1006129</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pgen.1006129">doi:10.1371/journal.pgen.1006129</ext-link>)<pub-id pub-id-type="pmid">27352031</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>JI</given-names></name><etal>et al.</etal></person-group>
<year>2005</year>
<article-title>Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>102</volume>, <fpage>17 551</fpage>–<lpage>17 558</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0507856102">doi:10.1073/pnas.0507856102</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shiota</surname><given-names>K</given-names></name></person-group>
<year>2003</year>
<article-title>Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>4806</fpage>–<lpage>4812</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M209923200">doi:10.1074/jbc.M209923200</ext-link>)<pub-id pub-id-type="pmid">12473678</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C83">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kokura</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kaul</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Wadhwa</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nomura</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Shinagawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yasukawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Colmenares</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ishii</surname><given-names>S</given-names></name></person-group>
<year>2001</year>
<article-title>The Ski protein family is required for MeCP2-mediated transcriptional repression</article-title>. <source/>J. Biol. Chem.
<volume>276</volume>, <fpage>34 115</fpage>–<lpage>34 121</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M105747200">doi:10.1074/jbc.M105747200</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Maclean</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nasir</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lafuente</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Shu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Kriaucionis</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>2007</year>
<article-title>Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>104</volume>, <fpage>2709</fpage>–<lpage>2714</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0608056104">doi:10.1073/pnas.0608056104</ext-link>)<pub-id pub-id-type="pmid">17296936</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>VH</given-names></name>, <name name-style="western"><surname>McBryant</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Wade</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Woodcock</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>JC</given-names></name></person-group>
<year>2007</year>
<article-title>Intrinsic disorder and autonomous domain function in the multifunctional nuclear protein, MeCP2</article-title>. <source/>J. Biol. Chem.
<volume>282</volume>, <fpage>15 057</fpage>–<lpage>15 064</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M700855200">doi:10.1074/jbc.M700855200</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mollica</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bessa</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Hanoulle</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Blackledge</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>R</given-names></name></person-group>
<year>2016</year>
<article-title>Binding mechanisms of intrinsically disordered proteins: theory, simulation, and experiment</article-title>. <source/>Front. Mol. Biosci.
<volume>3</volume>, <fpage>52</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fmolb.2016.00052">doi:10.3389/fmolb.2016.00052</ext-link>)<pub-id pub-id-type="pmid">27668217</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ausió</surname><given-names>J</given-names></name>, <name name-style="western"><surname>de Paz</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Esteller</surname><given-names>M</given-names></name></person-group>
<year>2014</year>
<article-title>MeCP2: the long trip from a chromatin protein to neurological disorders</article-title>. <source/>Trends Mol. Med.
<volume>20</volume>, <fpage>487</fpage>–<lpage>498</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molmed.2014.03.004">doi:10.1016/j.molmed.2014.03.004</ext-link>)<pub-id pub-id-type="pmid">24766768</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellini</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>MeCP2 post-translational modifications: a mechanism to control its involvement in synaptic plasticity and homeostasis?</article-title>
<source/>Front. Cell. Neurosci.
<volume>8</volume>, <fpage>236</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fncel.2014.00236">doi:10.3389/fncel.2014.00236</ext-link>)<pub-id pub-id-type="pmid">25165434</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Shachar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chahrour</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Thaller</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group>
<year>2009</year>
<article-title>Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus</article-title>. <source/>Hum. Mol. Genet.
<volume>18</volume>, <fpage>2431</fpage>–<lpage>2442</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddp181">doi:10.1093/hmg/ddp181</ext-link>)<pub-id pub-id-type="pmid">19369296</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacheco</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Heaven</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Holt</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Crossman</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Boggio</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Shaffer</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Flint</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Olsen</surname><given-names>ML</given-names></name></person-group>
<year>2017</year>
<article-title>RNA sequencing and proteomics approaches reveal novel deficits in the cortex of Mecp2-deficient mice, a model for Rett syndrome</article-title>. <source/>Mol. Autism
<volume>8</volume>, <fpage>56</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13229-017-0174-4">doi:10.1186/s13229-017-0174-4</ext-link>)<pub-id pub-id-type="pmid">29090078</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenson</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Ball</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>Mort</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Phillips</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Shiel</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>NST</given-names></name>, <name name-style="western"><surname>Abeysinghe</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Krawczak</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>DN</given-names></name></person-group>
<year>2003</year>
<article-title>Human Gene Mutation Database (HGMD): 2003 update</article-title>. <source/>Hum. Mutat.
<volume>21</volume>, <fpage>577</fpage>–<lpage>581</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/humu.10212">doi:10.1002/humu.10212</ext-link>)<pub-id pub-id-type="pmid">12754702</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Monk</surname><given-names>M</given-names></name></person-group>
<year>1998</year>
<article-title>Regulation of X-chromosome inactivation in development in mice and humans</article-title>. <source/>Microbiol. Mol. Biol. Rev.
<volume>62</volume>, <fpage>362</fpage>–<lpage>378</lpage>.<pub-id pub-id-type="pmid">9618446</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millar</surname><given-names>CB</given-names></name></person-group>
<year>2002</year>
<article-title>Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice</article-title>. <source/>Science
<volume>297</volume>, <fpage>403</fpage>–<lpage>405</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1073354">doi:10.1126/science.1073354</ext-link>)<pub-id pub-id-type="pmid">12130785</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trappe</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Laccone</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cobilanschi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Meins</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Huppke</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hanefeld</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Engel</surname><given-names>W</given-names></name></person-group>
<year>2001</year>
<article-title>MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin</article-title>. <source/>Am. J. Hum. Genet.
<volume>68</volume>, <fpage>1093</fpage>–<lpage>1101</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/320109">doi:10.1086/320109</ext-link>)<pub-id pub-id-type="pmid">11309679</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bienvenu</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<year>2000</year>
<article-title>MECP2 mutations account for most cases of typical forms of Rett syndrome</article-title>. <source/>Hum. Mol. Genet.
<volume>9</volume>, <fpage>1377</fpage>–<lpage>1384</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/HMG/9.9.1377">doi:10.1093/HMG/9.9.1377</ext-link>)<pub-id pub-id-type="pmid">10814719</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuddapah</surname><given-names>VA</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome</article-title>. <source/>J. Med. Genet.
<volume>51</volume>, <fpage>152</fpage>–<lpage>158</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/jmedgenet-2013-102113">doi:10.1136/jmedgenet-2013-102113</ext-link>)<pub-id pub-id-type="pmid">24399845</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>GPS</given-names></name>, <name name-style="western"><surname>Neilson</surname><given-names>TCS</given-names></name>, <name name-style="western"><surname>Pedersen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kerr</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hulten</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bailey</surname><given-names>MES</given-names></name>, <name name-style="western"><surname>Ørstavik</surname><given-names>KH</given-names></name></person-group>
<year>2006</year>
<article-title>Increased skewing of X chromosome inactivation in Rett syndrome patients and their mothers</article-title>. <source/>Eur. J. Hum. Genet.
<volume>14</volume>, <fpage>1189</fpage>–<lpage>1194</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.ejhg.5201682">doi:10.1038/sj.ejhg.5201682</ext-link>)<pub-id pub-id-type="pmid">16823396</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishii</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Makita</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ogawa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Amamiya</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Miyamoto</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Oki</surname><given-names>J</given-names></name></person-group>
<year>2001</year>
<article-title>The role of different X-inactivation pattern on the variable clinical phenotype with Rett syndrome</article-title>. <source/>Brain Dev.
<volume>23</volume>(<issue>Suppl. 1</issue>), <fpage>S161</fpage>–<lpage>S164</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0387-7604(01)00344-8">doi:10.1016/S0387-7604(01)00344-8</ext-link>)<pub-id pub-id-type="pmid">11738865</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffbuhr</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Moses</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Jerdonek</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Naidu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hoffman</surname><given-names>EP</given-names></name></person-group>
<year>2002</year>
<article-title>Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype</article-title>. <source/>Ment. Retard. Dev. Disabil. Res. Rev.
<volume>8</volume>, <fpage>99</fpage>–<lpage>105</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mrdd.10026">doi:10.1002/mrdd.10026</ext-link>)<pub-id pub-id-type="pmid">12112735</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben</surname><given-names>Zeev B</given-names></name>, <name name-style="western"><surname>Bebbington</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>H</given-names></name>, <name name-style="western"><surname>de Klerk</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Gak</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Vecsler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vecksler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Christodoulou</surname><given-names>J</given-names></name></person-group>
<year>2009</year>
<article-title>The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome</article-title>. <source/>Neurology
<volume>72</volume>, <fpage>1242</fpage>–<lpage>1247</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/01.wnl.0000345664.72220.6a">doi:10.1212/01.wnl.0000345664.72220.6a</ext-link>)<pub-id pub-id-type="pmid">19349604</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeev</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>Yaron</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Schanen</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Brandt</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ginot</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Shomrat</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Orr-Urtreger</surname><given-names>A</given-names></name></person-group>
<year>2002</year>
<article-title>Rett syndrome: clinical manifestations in males with MECP2 mutations</article-title>. <source/>J. Child Neurol.
<volume>17</volume>, <fpage>20</fpage>–<lpage>24</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/088307380201700105">doi:10.1177/088307380201700105</ext-link>)<pub-id pub-id-type="pmid">11913564</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jülich</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Horn</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Burfeind</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Erler</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Auber</surname><given-names>B</given-names></name></person-group>
<year>2009</year>
<article-title>A novel MECP2 mutation in a boy with neonatal encephalopathy and facial dysmorphism</article-title>. <source/>J. Pediatr.
<volume>155</volume>, <fpage>140</fpage>–<lpage>143</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jpeds.2009.01.035">doi:10.1016/j.jpeds.2009.01.035</ext-link>)<pub-id pub-id-type="pmid">19559301</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imessaoudene</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bonnefont</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Royer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cormier-Daire</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Lyonnet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lyon</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Munnich</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Amiel</surname><given-names>J</given-names></name></person-group>
<year>2001</year>
<article-title>MECP2 mutation in non-fatal, non-progressive encephalopathy in a male</article-title>. <source/>J. Med. Genet.
<volume>38</volume>, <fpage>171</fpage>–<lpage>174</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/jmg.38.3.171">doi:10.1136/jmg.38.3.171</ext-link>)<pub-id pub-id-type="pmid">11238684</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topçu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Akyerli</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sayi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Törüner</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Koçoğlu</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Cimbiş</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ozçelik</surname><given-names>T</given-names></name></person-group>
<year>2002</year>
<article-title>Somatic mosaicism for a MECP2 mutation associated with classic Rett syndrome in a boy</article-title>. <source/>Eur. J. Hum. Genet.
<volume>10</volume>, <fpage>77</fpage>–<lpage>81</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.ejhg.5200745">doi:10.1038/sj.ejhg.5200745</ext-link>)<pub-id pub-id-type="pmid">11896459</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartzman</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Bernardino</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nishimura</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gomes</surname><given-names>RR</given-names></name>, <name name-style="western"><surname>Zatz</surname><given-names>M</given-names></name></person-group>
<year>2001</year>
<article-title>Rett syndrome in a boy with a 47,XXY karyotype confirmed by a rare mutation in the MECP2 gene</article-title>. <source/>Neuropediatrics
<volume>32</volume>, <fpage>162</fpage>–<lpage>164</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1055/s-2001-16620">doi:10.1055/s-2001-16620</ext-link>)<pub-id pub-id-type="pmid">11521215</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meloni</surname><given-names>I</given-names></name><etal>et al.</etal></person-group>
<year>2000</year>
<article-title>A mutation in the rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males</article-title>. <source/>Am. J. Hum. Genet.
<volume>67</volume>, <fpage>982</fpage>–<lpage>985</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/303078">doi:10.1086/303078</ext-link>)<pub-id pub-id-type="pmid">10986043</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Esch</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<year>2005</year>
<article-title>Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males</article-title>. <source/>Am. J. Hum. Genet.
<volume>77</volume>, <fpage>442</fpage>–<lpage>453</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/444549">doi:10.1086/444549</ext-link>)<pub-id pub-id-type="pmid">16080119</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramocki</surname><given-names>MB</given-names></name><etal>et al.</etal></person-group>
<year>2009</year>
<article-title>Autism and other neuropsychiatric symptoms are prevalent in individuals with <italic>MeCP2</italic> duplication syndrome</article-title>. <source/>Ann. Neurol.
<volume>66</volume>, <fpage>771</fpage>–<lpage>782</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ana.21715">doi:10.1002/ana.21715</ext-link>)<pub-id pub-id-type="pmid">20035514</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C109">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendrich</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tweedie</surname><given-names>S</given-names></name></person-group>
<year>2003</year>
<article-title>The methyl-CpG binding domain and the evolving role of DNA methylation in animals</article-title>. <source/>Trends Genet.
<volume>19</volume>, <fpage>269</fpage>–<lpage>277</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0168-9525(03)00080-5">doi:10.1016/S0168-9525(03)00080-5</ext-link>)<pub-id pub-id-type="pmid">12711219</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C110">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pietri</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Roman</surname><given-names>A-C</given-names></name>, <name name-style="western"><surname>Guyon</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Romano</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Washbourne</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Moens</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>de Polavieja</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Sumbre</surname><given-names>G</given-names></name></person-group>
<year>2013</year>
<article-title>The first mecp2-null zebrafish model shows altered motor behaviors</article-title>. <source/>Front. Neural Circuits
<volume>7</volume>, <fpage>118</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fncir.2013.00118">doi:10.3389/fncir.2013.00118</ext-link>)<pub-id pub-id-type="pmid">23874272</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C111">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortelazzo</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Proteomic analysis of the Rett syndrome experimental model <italic>mecp2<sup>Q63X</sup></italic> mutant zebrafish</article-title>. <source/>J. Proteomics
<volume>154</volume>, <fpage>128</fpage>–<lpage>133</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jprot.2016.12.010">doi:10.1016/j.jprot.2016.12.010</ext-link>)<pub-id pub-id-type="pmid">28062374</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C112">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Svoboda</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Weijts</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Espin-Palazon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sapp</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Pietri</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bagnat</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Muotri</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Traver</surname><given-names>D</given-names></name></person-group>
<year>2017</year>
<article-title>Mecp2 regulates <italic>tnfa</italic> during zebrafish embryonic development and acute inflammation</article-title>. <source/>Dis. Model. Mech.
<volume>19</volume>, <fpage>1439</fpage>–<lpage>1451</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1242/dmm.026922">doi:10.1242/dmm.026922</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C113">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Modeling Rett syndrome ising TALEN-Edited MECP2 mutant cynomolgus monkeys</article-title>. <source/>Cell
<volume>169</volume>, <fpage>945</fpage>–<lpage>955</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2017.04.035">doi:10.1016/j.cell.2017.04.035</ext-link>)<pub-id pub-id-type="pmid">28525759</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C114">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patterson</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Hawkins</surname><given-names>VE</given-names></name>, <name name-style="western"><surname>Arps</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Mulkey</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Olsen</surname><given-names>ML</given-names></name></person-group>
<year>2015</year>
<article-title>MeCP2 deficiency results in robust Rett-like behavioural and motor deficits in male and female rats</article-title>. <source/>Hum. Mol. Genet.
<volume>25</volume>, <fpage>3303</fpage>–<lpage>3320</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddw179">doi:10.1093/hmg/ddw179</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C115">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veeraragavan</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Loss of MeCP2 in the rat models regression, impaired sociability and transcriptional deficits of Rett syndrome</article-title>. <source/>Hum. Mol. Genet.
<volume>25</volume>, <fpage>3284</fpage>–<lpage>3302</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddw178">doi:10.1093/hmg/ddw178</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C116">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Xing</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name></person-group>
<year>2016</year>
<article-title>Characterization of Rett syndrome-like phenotypes in Mecp2-knockout rats</article-title>. <source/>J. Neurodev. Disord.
<volume>8</volume>, <fpage>23</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s11689-016-9156-7">doi:10.1186/s11689-016-9156-7</ext-link>)<pub-id pub-id-type="pmid">27313794</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C117">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hendrich</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>2001</year>
<article-title>A mouse <italic>Mecp2</italic>-null mutation causes neurological symptoms that mimic Rett syndrome</article-title>. <source/>Nat. Genet.
<volume>27</volume>, <fpage>322</fpage>–<lpage>326</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/85899">doi:10.1038/85899</ext-link>)<pub-id pub-id-type="pmid">11242117</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C118">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Alvarez-saavedra</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sáez</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Saona</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>JI</given-names></name></person-group>
<year>2008</year>
<article-title>Defective body-weight regulation, motor control and abnormal social interactions in Mecp2 hypomorphic mice</article-title>. <source/>Hum. Mol. Genet.
<volume>17</volume>, <fpage>1707</fpage>–<lpage>1717</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddn061">doi:10.1093/hmg/ddn061</ext-link>)<pub-id pub-id-type="pmid">18321865</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C119">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samaco</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Fryer</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fyffe</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chao</surname><given-names>HT</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Greer</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Neul</surname><given-names>JL</given-names></name></person-group>
<year>2008</year>
<article-title>A partial loss of function allele of Methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome</article-title>. <source/>Hum. Mol. Genet.
<volume>17</volume>, <fpage>1718</fpage>–<lpage>1727</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddn062">doi:10.1093/hmg/ddn062</ext-link>)<pub-id pub-id-type="pmid">18321864</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C120">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>RZ</given-names></name>, <name name-style="western"><surname>Akbarian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tudor</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jaenisch</surname><given-names>R</given-names></name></person-group>
<year>2001</year>
<article-title>Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice</article-title>. <source/>Nat. Genet.
<volume>27</volume>, <fpage>327</fpage>–<lpage>331</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/85906">doi:10.1038/85906</ext-link>)<pub-id pub-id-type="pmid">11242118</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C121">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>DM</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Preclinical research in Rett syndrome: setting the foundation for translational success</article-title>. <source/>Dis. Model. Mech.
<volume>5</volume>, <fpage>733</fpage>–<lpage>745</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1242/dmm.011007">doi:10.1242/dmm.011007</ext-link>)<pub-id pub-id-type="pmid">23115203</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C122">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedogni</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms</article-title>. <source/>Cereb. Cortex
<volume>26</volume>, <fpage>2517</fpage>–<lpage>2529</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cercor/bhv078">doi:10.1093/cercor/bhv078</ext-link>)<pub-id pub-id-type="pmid">25979088</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C123">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Silva-Fernandes</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Oliveira</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sousa</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Maciel</surname><given-names>P</given-names></name></person-group>
<year>2007</year>
<article-title>Evidence for abnormal early development in a mouse model of Rett syndrome</article-title>. <source/>Genes Brain Behav.
<volume>6</volume>, <fpage>277</fpage>–<lpage>286</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1601-183X.2006.00258.x">doi:10.1111/j.1601-183X.2006.00258.x</ext-link>)<pub-id pub-id-type="pmid">16848781</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C124">
<label>124</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>H-TT</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>HYY</given-names></name>, <name name-style="western"><surname>Rosenmund</surname><given-names>C</given-names></name></person-group>
<year>2007</year>
<article-title>MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number</article-title>. <source/>Neuron
<volume>56</volume>, <fpage>58</fpage>–<lpage>65</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuron.2007.08.018">doi:10.1016/j.neuron.2007.08.018</ext-link>)<pub-id pub-id-type="pmid">17920015</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C125">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gigli</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Scaramuzza</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gandaglia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bellini</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gabaglio</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Parolaro</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kilstrup-Nielsen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Landsberger</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bedogni</surname><given-names>F</given-names></name></person-group>
<year>2016</year>
<article-title>MeCP2 related studies benefit from the use of CD1 as genetic background</article-title>. <source/>PLoS ONE
<volume>11</volume>, <fpage>e0153473</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0153473">doi:10.1371/journal.pone.0153473</ext-link>)<pub-id pub-id-type="pmid">27097329</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C126">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahbazian</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Yuva-Paylor</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Spencer</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Antalffy</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Noebels</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Paylor</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group>
<year>2002</year>
<article-title>Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3</article-title>. <source/>Neuron
<volume>35</volume>, <fpage>243</fpage>–<lpage>254</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0896-6273(02)00768-7">doi:10.1016/S0896-6273(02)00768-7</ext-link>)<pub-id pub-id-type="pmid">12160743</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C127">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawson-Yuen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>ZI</given-names></name>, <name name-style="western"><surname>Tsai</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Basu</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Picker</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Coyle</surname><given-names>JT</given-names></name></person-group>
<year>2007</year>
<article-title>Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice</article-title>. <source/>Brain Res.
<volume>1180</volume>, <fpage>1</fpage>–<lpage>6</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.brainres.2007.08.039">doi:10.1016/j.brainres.2007.08.039</ext-link>)<pub-id pub-id-type="pmid">17936729</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C128">
<label>128</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wegener</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Characterization of the MeCP2R168X knockin mouse model for Rett syndrome</article-title>. <source/>PLoS ONE
<volume>9</volume>, <fpage>e115444</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0115444">doi:10.1371/journal.pone.0115444</ext-link>)<pub-id pub-id-type="pmid">25541993</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C129">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<year>2009</year>
<article-title>Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>106</volume>, <fpage>4882</fpage>–<lpage>4887</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0811648106">doi:10.1073/pnas.0811648106</ext-link>)<pub-id pub-id-type="pmid">19225110</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C130">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jentarra</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Olfers</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Rice</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Homanics</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Blue</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Naidu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Narayanan</surname><given-names>V</given-names></name></person-group>
<year>2010</year>
<article-title>Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140 V mouse model of Rett syndrome/X-linked mental retardation</article-title>. <source/>BMC Neurosci.
<volume>11</volume>, <fpage>19</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2202-11-19">doi:10.1186/1471-2202-11-19</ext-link>)<pub-id pub-id-type="pmid">20163734</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C131">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function</article-title>. <source/>Neuron
<volume>72</volume>, <fpage>72</fpage>–<lpage>85</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuron.2011.08.022">doi:10.1016/j.neuron.2011.08.022</ext-link>)<pub-id pub-id-type="pmid">21982370</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C132">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goffin</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>Rett syndrome mutation MeCP2 T1 58A disrupts DNA binding, protein stability and ERP responses</article-title>. <source/>Nat. Neurosci.
<volume>15</volume>, <fpage>274</fpage>–<lpage>283</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nn.2997">doi:10.1038/nn.2997</ext-link>)<pub-id pub-id-type="pmid">22119903</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C133">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itoh</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tahimic</surname><given-names>CGT</given-names></name>, <name name-style="western"><surname>Ide</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Otsuki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sasaoka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Noguchi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Oshimura</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Goto</surname><given-names>YI</given-names></name>, <name name-style="western"><surname>Kurimasa</surname><given-names>A</given-names></name></person-group>
<year>2012</year>
<article-title>Methyl CpG-binding protein isoform MeCP2-e2 is dispensable for Rett syndrome phenotypes but essential for embryo viability and placenta development</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>13 859</fpage>–<lpage>13 867</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M111.309864">doi:10.1074/jbc.M111.309864</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C134">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasui</surname><given-names>DH</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Mice with an isoform-ablating Mecp2 exon 1 mutation recapitulate the neurologic deficits of Rett syndrome</article-title>. <source/>Hum. Mol. Genet.
<volume>23</volume>, <fpage>2447</fpage>–<lpage>2458</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddt640">doi:10.1093/hmg/ddt640</ext-link>)<pub-id pub-id-type="pmid">24352790</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C135">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome</article-title>. <source/>Hum. Mol. Genet.
<volume>25</volume>, <fpage>558</fpage>–<lpage>570</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddv496">doi:10.1093/hmg/ddv496</ext-link>)<pub-id pub-id-type="pmid">26647311</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C136">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitcher</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Herrera</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Buffington</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Kochukov</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Merritt</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Schanen</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Costa-Mattioli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Neul</surname><given-names>JL</given-names></name></person-group>
<year>2015</year>
<article-title>Rett syndrome like phenotypes in the R255X Mecp2 mutant mouse are rescued by MECP2 transgene</article-title>. <source/>Hum. Mol. Genet.
<volume>24</volume>, <fpage>2662</fpage>–<lpage>2672</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddv030">doi:10.1093/hmg/ddv030</ext-link>)<pub-id pub-id-type="pmid">25634563</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C137">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamonica</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>DY</given-names></name>, <name name-style="western"><surname>Goffin</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fenik</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Veasey</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name></person-group>
<year>2017</year>
<article-title>Elevating expression of MeCP2T158M rescues DNA binding and Rett syndrome-like phenotypes</article-title>. <source/>J. Clin. Invest.
<volume>127</volume>, <fpage>1889</fpage>–<lpage>1904</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI90967">doi:10.1172/JCI90967</ext-link>)<pub-id pub-id-type="pmid">28394263</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C138">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>BS</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Biotin tagging of MeCP2 in mice reveals contextual insights into the Rett syndrome transcriptome</article-title>. <source/>Nat. Med.
<volume>23</volume>, <fpage>1203</fpage>–<lpage>1214</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm.4406">doi:10.1038/nm.4406</ext-link>)<pub-id pub-id-type="pmid">28920956</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C139">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fyffe</surname><given-names>SL</given-names></name><etal>et al.</etal></person-group>
<year>2008</year>
<article-title>Deletion of Mecp2 in Sim1-expressing neurons reveals a critical role for MeCP2 in feeding behavior, aggression, and the response to stress</article-title>. <source/>Neuron
<volume>59</volume>, <fpage>947</fpage>–<lpage>958</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuron.2008.07.030">doi:10.1016/j.neuron.2008.07.030</ext-link>)<pub-id pub-id-type="pmid">18817733</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C140">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>XJ</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>YD</given-names></name>, <name name-style="western"><surname>Shu</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>ZL</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>XH</given-names></name></person-group>
<year>2014</year>
<article-title>Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity</article-title>. <source/>Nat. Commun.
<volume>5</volume>, <fpage>5036</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncomms6036">doi:10.1038/ncomms6036</ext-link>)<pub-id pub-id-type="pmid">25297674</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C141">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>V</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>MeCP2 affects skeletal muscle growth and morphology through non cell-autonomous mechanisms</article-title>. <source/>PLoS ONE
<volume>10</volume>, <fpage>e0130183</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0130183">doi:10.1371/journal.pone.0130183</ext-link>)<pub-id pub-id-type="pmid">26098633</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C142">
<label>142</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito-Ishida</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ure</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Swann</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group>
<year>2015</year>
<article-title>Loss of MeCP2 in parvalbumin-and somatostatin-expressing neurons in mice leads to distinct Rett syndrome-like phenotypes</article-title>. <source/>Neuron
<volume>88</volume>, <fpage>651</fpage>–<lpage>658</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuron.2015.10.029">doi:10.1016/j.neuron.2015.10.029</ext-link>)<pub-id pub-id-type="pmid">26590342</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C143">
<label>143</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name></person-group>
<year>2012</year>
<article-title>Beyond widespread Mecp2 deletions to model Rett syndrome: conditional spatio-temporal knockout, single-point mutations and transgenic rescue mice</article-title>. <source/>Autism Open Access
<volume>2012</volume>(<issue>Suppl. 1</issue>), <fpage>5</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4172/2165-7890.S1-005">doi:10.4172/2165-7890.S1-005</ext-link>)<pub-id pub-id-type="pmid">23946910</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C144">
<label>144</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Dunn</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Antalffy</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Trivedi</surname><given-names>R</given-names></name></person-group>
<year>1995</year>
<article-title>Selective dendritic alterations in the cortex of Rett syndrome</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>54</volume>, <fpage>195</fpage>–<lpage>201</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00005072-199503000-00006">doi:10.1097/00005072-199503000-00006</ext-link>)<pub-id pub-id-type="pmid">7876888</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C145">
<label>145</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Selfridge</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cobb</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>2007</year>
<article-title>Reversal of neurological defects in a mouse model of Rett syndrome</article-title>. <source/>Science
<volume>315</volume>, <fpage>1143</fpage>–<lpage>1147</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1138389">doi:10.1126/science.1138389</ext-link>)<pub-id pub-id-type="pmid">17289941</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C146">
<label>146</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nawaz</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>J</given-names></name></person-group>
<year>2000</year>
<article-title>Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3</article-title>. <source/>EMBO J.
<volume>19</volume>, <fpage>4342</fpage>–<lpage>4350</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/emboj/19.16.4342">doi:10.1093/emboj/19.16.4342</ext-link>)<pub-id pub-id-type="pmid">10944117</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C147">
<label>147</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>H-G</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Reynolds</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>J</given-names></name></person-group>
<year>2003</year>
<article-title>N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso</article-title>. <source/>Mol. Cell
<volume>12</volume>, <fpage>723</fpage>–<lpage>734</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molcel.2003.08.008">doi:10.1016/j.molcel.2003.08.008</ext-link>)<pub-id pub-id-type="pmid">14527417</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C148">
<label>148</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischle</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Dequiedt</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hendzel</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Guenther</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Lazar</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Voelter</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Verdin</surname><given-names>E</given-names></name></person-group>
<year>2002</year>
<article-title>Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR</article-title>. <source/>Mol. Cell
<volume>9</volume>, <fpage>45</fpage>–<lpage>57</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1097-2765(01)00429-4">doi:10.1016/S1097-2765(01)00429-4</ext-link>)<pub-id pub-id-type="pmid">11804585</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C149">
<label>149</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mottis</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mouchiroud</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Auwerx</surname><given-names>J</given-names></name></person-group>
<year>2013</year>
<article-title>Emerging roles of the corepressors NCoR1 and SMRT in homeostasis</article-title>. <source/>Genes Dev.
<volume>27</volume>, <fpage>819</fpage>–<lpage>835</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gad.214023.113">doi:10.1101/gad.214023.113</ext-link>)<pub-id pub-id-type="pmid">23630073</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C150">
<label>150</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruusvee</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Lyst</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tarnauskaitė</surname><given-names>Ž</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Cook</surname><given-names>AG</given-names></name></person-group>
<year>2017</year>
<article-title>Structure of the MeCP2–TBLR1 complex reveals a molecular basis for Rett syndrome and related disorders</article-title>. <source/>Proc. Natl. Acad. Sci. USA
<volume>114</volume>, <fpage>E3243</fpage>–<lpage>E3250</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1700731114">doi:10.1073/pnas.1700731114</ext-link>)<pub-id pub-id-type="pmid">28348241</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C151">
<label>151</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tudor</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Akbarian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>RZ</given-names></name>, <name name-style="western"><surname>Jaenisch</surname><given-names>R</given-names></name></person-group>
<year>2002</year>
<article-title>Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>99</volume>, <fpage>15 536</fpage>–<lpage>15 541</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.242566899">doi:10.1073/pnas.242566899</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C152">
<label>152</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Kwan</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Francke</surname><given-names>U</given-names></name></person-group>
<year>2007</year>
<article-title>Cerebellar gene expression profiles of mouse models for Rett syndrome reveal novel MeCP2 targets</article-title>. <source/>BMC Med. Genet.
<volume>8</volume>, <fpage>36</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2350-8-36">doi:10.1186/1471-2350-8-36</ext-link>)<pub-id pub-id-type="pmid">17584923</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C153">
<label>153</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyst</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>2015</year>
<article-title>Rett syndrome: a complex disorder with simple roots</article-title>. <source/>Nat. Rev. Genet.
<volume>16</volume>, <fpage>261</fpage>–<lpage>275</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrg3897">doi:10.1038/nrg3897</ext-link>)<pub-id pub-id-type="pmid">25732612</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C154">
<label>154</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heckman</surname><given-names>LDD</given-names></name>, <name name-style="western"><surname>Chahrour</surname><given-names>MHH</given-names></name>, <name name-style="western"><surname>Zoghbi</surname><given-names>HYY</given-names></name></person-group>
<year>2014</year>
<article-title>Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice</article-title>. <source/>Elife
<volume>3</volume>, <fpage>e02676</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.7554/eLife.02676">doi:10.7554/eLife.02676</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C155">
<label>155</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tillotson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Selfridge</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Koerner</surname><given-names>MV</given-names></name>, <name name-style="western"><surname>Gadalla</surname><given-names>KKE</given-names></name>, <name name-style="western"><surname>Guy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>De Sousa</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hector</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Cobb</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>2017</year>
<article-title>Radically truncated MeCP2 rescues Rett syndrome-like neurological defects</article-title>. <source/>Nature
<volume>550</volume>, <fpage>398</fpage>–<lpage>401</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature24058">doi:10.1038/nature24058</ext-link>)<pub-id pub-id-type="pmid">29019980</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C156">
<label>156</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchovecky</surname><given-names>CM</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome</article-title>. <source/>Nat. Genet.
<volume>45</volume>, <fpage>1013</fpage>–<lpage>1020</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2714">doi:10.1038/ng.2714</ext-link>)<pub-id pub-id-type="pmid">23892605</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C157">
<label>157</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porter</surname><given-names>TD</given-names></name></person-group>
<year>2012</year>
<article-title>New insights into the role of cytochrome P450 reductase (POR) in microsomal redox biology</article-title>. <source/>Acta Pharm. Sin. B
<volume>2</volume>, <fpage>102</fpage>–<lpage>106</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.apsb.2012.02.002">doi:10.1016/j.apsb.2012.02.002</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C158">
<label>158</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osono</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Woollett</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Herz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dietschy</surname><given-names>JM</given-names></name></person-group>
<year>1995</year>
<article-title>Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse</article-title>. <source/>J. Clin. Invest.
<volume>95</volume>, <fpage>1124</fpage>–<lpage>1132</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI117760">doi:10.1172/JCI117760</ext-link>)<pub-id pub-id-type="pmid">7883961</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C159">
<label>159</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Der Wulp</surname><given-names>MYM</given-names></name>, <name name-style="western"><surname>Verkade</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Groen</surname><given-names>AK</given-names></name></person-group>
<year>2013</year>
<article-title>Regulation of cholesterol homeostasis</article-title>. <source/>Mol. Cell. Endocrinol.
<volume>368</volume>, <fpage>1</fpage>–<lpage>16</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.mce.2012.06.007">doi:10.1016/j.mce.2012.06.007</ext-link>)<pub-id pub-id-type="pmid">22721653</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C160">
<label>160</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfrieger</surname><given-names>FW</given-names></name>, <name name-style="western"><surname>Ungerer</surname><given-names>N</given-names></name></person-group>
<year>2011</year>
<article-title>Cholesterol metabolism in neurons and astrocytes</article-title>. <source/>Prog. Lipid Res.
<volume>50</volume>, <fpage>357</fpage>–<lpage>371</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.plipres.2011.06.002">doi:10.1016/j.plipres.2011.06.002</ext-link>)<pub-id pub-id-type="pmid">21741992</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C161">
<label>161</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group>
<year>2008</year>
<article-title>The blood-brain barrier in health and chronic neurodegenerative disorders</article-title>. <source/>Neuron
<volume>57</volume>, <fpage>178</fpage>–<lpage>201</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuron.2008.01.003">doi:10.1016/j.neuron.2008.01.003</ext-link>)<pub-id pub-id-type="pmid">18215617</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C162">
<label>162</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lund</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kotti</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Turley</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Dietschy</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Russell</surname><given-names>DW</given-names></name></person-group>
<year>2003</year>
<article-title>Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>22 980</fpage>–<lpage>22 988</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M303415200">doi:10.1074/jbc.M303415200</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C163">
<label>163</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lund</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Guileyardo</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Russell</surname><given-names>DW</given-names></name></person-group>
<year>1999</year>
<article-title>cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>96</volume>, <fpage>7238</fpage>–<lpage>7243</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.96.13.7238">doi:10.1073/pnas.96.13.7238</ext-link>)<pub-id pub-id-type="pmid">10377398</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C164">
<label>164</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bi</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>G</given-names></name></person-group>
<year>2010</year>
<article-title>Cholesterol in Niemann–Pick type C disease</article-title>. <source/>Subcell. Biochem.
<volume>51</volume>, <fpage>319</fpage>–<lpage>335</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/978-90-481-8622-8_11">doi:10.1007/978-90-481-8622-8_11</ext-link>)<pub-id pub-id-type="pmid">20213549</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C165">
<label>165</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tint</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Irons</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Elias</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Batta</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Frieden</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Salen</surname><given-names>G</given-names></name></person-group>
<year>1994</year>
<article-title>Defective cholesterol biosynthesis associated with the Smith–Lemli–Opitz syndrome</article-title>. <source/>N. Engl. J. Med.
<volume>330</volume>, <fpage>107</fpage>–<lpage>113</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJM199401133300205">doi:10.1056/NEJM199401133300205</ext-link>)<pub-id pub-id-type="pmid">8259166</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C166">
<label>166</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berry-Kravis</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Levin</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Mathur</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Darnell</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Ouyang</surname><given-names>B</given-names></name></person-group>
<year>2015</year>
<article-title>Cholesterol levels in Fragile X syndrome</article-title>. <source/>Am. J. Med. Genet. Part A
<volume>167</volume>, <fpage>379</fpage>–<lpage>384</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajmg.a.36850">doi:10.1002/ajmg.a.36850</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C167">
<label>167</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Khalik</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Defective cholesterol metabolism in amyotrophic lateral sclerosis</article-title>. <source/>J. Lipid Res.
<volume>58</volume>, <fpage>267</fpage>–<lpage>278</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1194/jlr.P071639">doi:10.1194/jlr.P071639</ext-link>)<pub-id pub-id-type="pmid">27811233</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C168">
<label>168</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puglielli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tanzi</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Kovacs</surname><given-names>DM</given-names></name></person-group>
<year>2003</year>
<article-title>Alzheimer's disease: the cholesterol connection</article-title>. <source/>Nat. Neurosci.
<volume>6</volume>, <fpage>345</fpage>–<lpage>351</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nn0403-345">doi:10.1038/nn0403-345</ext-link>)<pub-id pub-id-type="pmid">12658281</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C169">
<label>169</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Lau</surname><given-names>LML</given-names></name>, <name name-style="western"><surname>Koudstaal</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Hofman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Breteler</surname><given-names>MMB</given-names></name></person-group>
<year>2006</year>
<article-title>Serum cholesterol levels and the risk of Parkinson's disease</article-title>. <source/>Am. J. Epidemiol.
<volume>164</volume>, <fpage>998</fpage>–<lpage>1002</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/aje/kwj283">doi:10.1093/aje/kwj283</ext-link>)<pub-id pub-id-type="pmid">16905642</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C170">
<label>170</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karasinska</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Hayden</surname><given-names>MR</given-names></name></person-group>
<year>2011</year>
<article-title>Cholesterol metabolism in Huntington disease</article-title>. <source/>Nat. Rev. Neurol.
<volume>7</volume>, <fpage>561</fpage>–<lpage>572</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrneurol.2011.132">doi:10.1038/nrneurol.2011.132</ext-link>)<pub-id pub-id-type="pmid">21894212</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C171">
<label>171</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Chuang</surname><given-names>J-C</given-names></name>, <name name-style="western"><surname>Posey</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Turley</surname><given-names>SD</given-names></name></person-group>
<year>2017</year>
<article-title>Suppression of brain cholesterol synthesis in male Mecp2-deficient mice is age dependent and not accompanied by a concurrent change in the rate of fatty acid synthesis</article-title>. <source/>Brain Res.
<volume>1654A</volume>, <fpage>77</fpage>–<lpage>84</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.brainres.2016.10.021">doi:10.1016/j.brainres.2016.10.021</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C172">
<label>172</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietschy</surname><given-names>JM</given-names></name></person-group>
<year>2009</year>
<article-title>Central nervous system: cholesterol turnover, brain development and neurodegeneration</article-title>. <source/>Biol. Chem.
<volume>390</volume>, <fpage>287</fpage>–<lpage>293</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1515/BC.2009.035">doi:10.1515/BC.2009.035</ext-link>)<pub-id pub-id-type="pmid">19166320</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C173">
<label>173</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sticozzi</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Scavenger receptor B1 post-translational modifications in Rett syndrome</article-title>. <source/>FEBS Lett.
<volume>587</volume>, <fpage>2199</fpage>–<lpage>2204</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.febslet.2013.05.042">doi:10.1016/j.febslet.2013.05.042</ext-link>)<pub-id pub-id-type="pmid">23711372</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C174">
<label>174</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shapiro</surname><given-names>JR</given-names></name><etal>et al.</etal></person-group>
<year>2010</year>
<article-title>Bone mass in Rett syndrome: association with clinical parameters and MECP2 mutations</article-title>. <source/>Pediatr. Res.
<volume>68</volume>, <fpage>446</fpage>–<lpage>451</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1203/PDR.0b013e3181f2edd2">doi:10.1203/PDR.0b013e3181f2edd2</ext-link>)<pub-id pub-id-type="pmid">20661168</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C175">
<label>175</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motil</surname><given-names>KJ</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>Vitamin D deficiency is prevalent in girls and women with Rett syndrome</article-title>. <source/>J. Pediatr. Gastroenterol. Nutr.
<volume>53</volume>, <fpage>569</fpage>–<lpage>574</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MPG.0b013e3182267a66">doi:10.1097/MPG.0b013e3182267a66</ext-link>)<pub-id pub-id-type="pmid">21637127</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C176">
<label>176</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motil</surname><given-names>KJ</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome</article-title>. <source/>J. Pediatr. Gastroenterol. Nutr.
<volume>55</volume>, <fpage>292</fpage>–<lpage>298</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MPG.0b013e31824b6159">doi:10.1097/MPG.0b013e31824b6159</ext-link>)<pub-id pub-id-type="pmid">22331013</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C177">
<label>177</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Bugge</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mullican</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Alenghat</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>XS</given-names></name>, <name name-style="western"><surname>Lazar</surname><given-names>MA</given-names></name></person-group>
<year>2011</year>
<article-title>A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism</article-title>. <source/>Science
<volume>331</volume>, <fpage>1315</fpage>–<lpage>1319</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1198125">doi:10.1126/science.1198125</ext-link>)<pub-id pub-id-type="pmid">21393543</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C178">
<label>178</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knutson</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Chyla</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Amann</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Bhaskara</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Huppert</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Hiebert</surname><given-names>SW</given-names></name></person-group>
<year>2008</year>
<article-title>Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks</article-title>. <source/>EMBO J.
<volume>27</volume>, <fpage>1017</fpage>–<lpage>1028</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/emboj.2008.51">doi:10.1038/emboj.2008.51</ext-link>)<pub-id pub-id-type="pmid">18354499</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C179">
<label>179</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration</article-title>. <source/>Nat. Med.
<volume>18</volume>, <fpage>934</fpage>–<lpage>942</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm.2744">doi:10.1038/nm.2744</ext-link>)<pub-id pub-id-type="pmid">22561686</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C180">
<label>180</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyle</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Saha</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Justice</surname><given-names>MJ</given-names></name></person-group>
<year>2016</year>
<article-title>MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex</article-title>. <source/>Hum. Mol. Genet.
<volume>25</volume>, <fpage>3029</fpage>–<lpage>3041</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddw156">doi:10.1093/hmg/ddw156</ext-link>)<pub-id pub-id-type="pmid">27288453</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C181">
<label>181</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Istvan</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Deisenhofer</surname><given-names>J</given-names></name></person-group>
<year>2001</year>
<article-title>Structural mechanism for statin inhibition of HMG-CoA reductase</article-title>. <source/>Science
<volume>292</volume>, <fpage>1160</fpage>–<lpage>1164</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1059344">doi:10.1126/science.1059344</ext-link>)<pub-id pub-id-type="pmid">11349148</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C182">
<label>182</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weitz-Schmidt</surname><given-names>G</given-names></name></person-group>
<year>2002</year>
<article-title>Statins as anti-inflammatory agents</article-title>. <source/>Trends Pharmacol. Sci.
<volume>23</volume>, <fpage>482</fpage>–<lpage>486</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0165-6147(02)02077-1">doi:10.1016/S0165-6147(02)02077-1</ext-link>)<pub-id pub-id-type="pmid">12368073</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C183">
<label>183</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Ridker</surname><given-names>PM</given-names></name></person-group>
<year>2005</year>
<article-title>Anti-inflammatory effects of statins: clinical evidence and basic mechanisms</article-title>. <source/>Nat. Rev. Drug Discov.
<volume>4</volume>, <fpage>977</fpage>–<lpage>987</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrd1901">doi:10.1038/nrd1901</ext-link>)<pub-id pub-id-type="pmid">16341063</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C184">
<label>184</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abd</surname><given-names>TT</given-names></name>, <name name-style="western"><surname>Jacobson</surname><given-names>TA</given-names></name></person-group>
<year>2011</year>
<article-title>Statin-induced myopathy: a review and update</article-title>. <source/>Expert Opin. Drug Saf.
<volume>10</volume>, <fpage>373</fpage>–<lpage>387</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1517/14740338.2011.540568">doi:10.1517/14740338.2011.540568</ext-link>)<pub-id pub-id-type="pmid">21342078</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C185">
<label>185</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strom</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Schinnar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Karlawish</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hennessy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Teal</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bilker</surname><given-names>WB</given-names></name></person-group>
<year>2015</year>
<article-title>Statin therapy and risk of acute memory impairment</article-title>. <source/>JAMA Intern. Med.
<volume>175</volume>, <fpage>1399</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jamainternmed.2015.2092">doi:10.1001/jamainternmed.2015.2092</ext-link>)<pub-id pub-id-type="pmid">26054031</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C186">
<label>186</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osterweil</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Chuang</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Chubykin</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Sidorov</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bianchi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>RKS</given-names></name>, <name name-style="western"><surname>Bear</surname><given-names>MF</given-names></name></person-group>
<year>2013</year>
<article-title>Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome</article-title>. <source/>Neuron
<volume>77</volume>, <fpage>243</fpage>–<lpage>250</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuron.2012.01.034">doi:10.1016/j.neuron.2012.01.034</ext-link>)<pub-id pub-id-type="pmid">23352161</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C187">
<label>187</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ardern-Holmes</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>North</surname><given-names>KN</given-names></name></person-group>
<year>2011</year>
<article-title>Therapeutics for childhood neurofibromatosis type 1 and type 2</article-title>. <source/>Curr. Treat. Options Neurol.
<volume>13</volume>, <fpage>529</fpage>–<lpage>543</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11940-011-0142-9">doi:10.1007/s11940-011-0142-9</ext-link>)<pub-id pub-id-type="pmid">21850405</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C188">
<label>188</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villani</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sacchetti</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bagnati</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Passoni</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fusco</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Carli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Invernizzi</surname><given-names>RW</given-names></name></person-group>
<year>2016</year>
<article-title>Lovastatin fails to improve motor performance and survival in methyl-CpG-binding protein2-null mice</article-title>. <source/>Elife
<volume>5</volume>, <fpage>e22409</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.7554/eLife.22409">doi:10.7554/eLife.22409</ext-link>)<pub-id pub-id-type="pmid">27892851</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C189">
<label>189</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nott</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>Histone deacetylase 3 associates with MeCP2 to regulate FOXO and social behavior</article-title>. <source/>Nat. Neurosci.
<volume>19</volume>, <fpage>1497</fpage>–<lpage>1505</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nn.4347">doi:10.1038/nn.4347</ext-link>)<pub-id pub-id-type="pmid">27428650</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C190">
<label>190</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skene</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Illingworth</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Webb</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kerr</surname><given-names>ARW</given-names></name>, <name name-style="western"><surname>James</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>AP</given-names></name></person-group>
<year>2010</year>
<article-title>Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state</article-title>. <source/>Mol. Cell
<volume>37</volume>, <fpage>457</fpage>–<lpage>468</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molcel.2010.01.030">doi:10.1016/j.molcel.2010.01.030</ext-link>)<pub-id pub-id-type="pmid">20188665</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C191">
<label>191</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfrieger</surname><given-names>FW</given-names></name></person-group>
<year>2003</year>
<article-title>Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes?</article-title>
<source/>Bioessays
<volume>25</volume>, <fpage>72</fpage>–<lpage>78</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/bies.10195">doi:10.1002/bies.10195</ext-link>)<pub-id pub-id-type="pmid">12508285</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C192">
<label>192</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballas</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Lioy</surname><given-names>DT</given-names></name>, <name name-style="western"><surname>Grunseich</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mandel</surname><given-names>G</given-names></name></person-group>
<year>2009</year>
<article-title>Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology</article-title>. <source/>Nat. Neurosci.
<volume>12</volume>, <fpage>311</fpage>–<lpage>317</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nn.2275">doi:10.1038/nn.2275</ext-link>)<pub-id pub-id-type="pmid">19234456</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C193">
<label>193</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lioy</surname><given-names>DT</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>A role for glia in the progression of Rett's syndrome</article-title>. <source/>Nature
<volume>475</volume>, <fpage>497</fpage>–<lpage>500</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature10214">doi:10.1038/nature10214</ext-link>)<pub-id pub-id-type="pmid">21716289</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C194">
<label>194</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>MVC</given-names></name>, <name name-style="western"><surname>Felice</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Covey</surname><given-names>MV</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Mandel</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ballas</surname><given-names>N</given-names></name></person-group>
<year>2013</year>
<article-title>Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology</article-title>. <source/>J. Neurosci.
<volume>33</volume>, <fpage>18 764</fpage>–<lpage>18 774</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1523/JNEUROSCI.2657-13.2013">doi:10.1523/JNEUROSCI.2657-13.2013</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C195">
<label>195</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooke</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Naidu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Plotnick</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Berkovitz</surname><given-names>GD</given-names></name></person-group>
<year>1995</year>
<article-title>Abnormalities of thyroid function and glucose control in subjects with Rett syndrome</article-title>. <source/>Horm. Res.
<volume>43</volume>, <fpage>273</fpage>–<lpage>278</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000184309">doi:10.1159/000184309</ext-link>)<pub-id pub-id-type="pmid">7607612</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C196">
<label>196</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogawa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sawaguchi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Furukawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Okajima</surname><given-names>T</given-names></name></person-group>
<year>2015</year>
<article-title>N-acetylglucosamine modification in the lumen of the endoplasmic reticulum</article-title>. <source/>Biochim. Biophys. Acta.
<volume>1850</volume>, <fpage>1319</fpage>–<lpage>1324</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbagen.2015.03.003">doi:10.1016/j.bbagen.2015.03.003</ext-link>)<pub-id pub-id-type="pmid">25791024</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C197">
<label>197</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olivier-Van Stichelen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hanover</surname><given-names>JA</given-names></name></person-group>
<year>2015</year>
<article-title>You are what you eat: O-linked N-acetylglucosamine in disease, development and epigenetics</article-title>. <source/>Curr. Opin. Clin. Nutr. Metab. Care
<volume>18</volume>, <fpage>339</fpage>–<lpage>345</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MCO.0000000000000188">doi:10.1097/MCO.0000000000000188</ext-link>)<pub-id pub-id-type="pmid">26049631</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C198">
<label>198</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hao</surname><given-names>J</given-names></name></person-group>
<year>2017</year>
<article-title>The emerging link between O-GlcNAcylation and neurological disorders</article-title>. <source/>Cell. Mol. Life Sci.
<volume>74</volume>, <fpage>3667</fpage>–<lpage>3686</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00018-017-2542-9">doi:10.1007/s00018-017-2542-9</ext-link>)<pub-id pub-id-type="pmid">28534084</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C199">
<label>199</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojas-Gutierrez</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Muñoz-Arenas</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Treviño</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Espinosa</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chavez</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rojas</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Flores</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Díaz</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Guevara</surname><given-names>J</given-names></name></person-group>
<year>2017</year>
<article-title>Alzheimer's disease and metabolic syndrome: a link from oxidative stress and inflammation to neurodegeneration</article-title>. <source/>Synapse
<volume>71</volume>, <fpage>e21990</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/syn.21990">doi:10.1002/syn.21990</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C200">
<label>200</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kriaucionis</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Paterson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Curtis</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Guy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>MacLeod</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A</given-names></name></person-group>
<year>2006</year>
<article-title>Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome</article-title>. <source/>Mol. Cell. Biol.
<volume>26</volume>, <fpage>5033</fpage>–<lpage>5042</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/MCB.01665-05">doi:10.1128/MCB.01665-05</ext-link>)<pub-id pub-id-type="pmid">16782889</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C201">
<label>201</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gold</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Williamson</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Kaur</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hargreaves</surname><given-names>IP</given-names></name>, <name name-style="western"><surname>Land</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Pelka</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Tam</surname><given-names>PPL</given-names></name>, <name name-style="western"><surname>Christodoulou</surname><given-names>J</given-names></name></person-group>
<year>2014</year>
<article-title>Mitochondrial dysfunction in the skeletal muscle of a mouse model of Rett syndrome (RTT): implications for the disease phenotype</article-title>. <source/>Mitochondrion
<volume>15</volume>, <fpage>10</fpage>–<lpage>17</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.mito.2014.02.012">doi:10.1016/j.mito.2014.02.012</ext-link>)<pub-id pub-id-type="pmid">24613463</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C202">
<label>202</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Müller</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Can</surname><given-names>K</given-names></name></person-group>
<year>2014</year>
<article-title>Aberrant redox homoeostasis and mitochondrial dysfunction in Rett syndrome</article-title>. <source/>Biochem. Soc. Trans.
<volume>42</volume>, <fpage>959</fpage>–<lpage>964</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/BST20140071">doi:10.1042/BST20140071</ext-link>)<pub-id pub-id-type="pmid">25109986</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C203">
<label>203</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Felice</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome</article-title>. <source/>Neurobiol. Dis.
<volume>68</volume>, <fpage>66</fpage>–<lpage>77</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.nbd.2014.04.006">doi:10.1016/j.nbd.2014.04.006</ext-link>)<pub-id pub-id-type="pmid">24769161</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C204">
<label>204</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulman</surname><given-names>IG</given-names></name></person-group>
<year>2017</year>
<article-title>Liver X receptors link lipid metabolism and inflammation</article-title>. <source/>FEBS Lett.
<volume>591</volume>, <fpage>2978</fpage>–<lpage>2991</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/1873-3468.12702">doi:10.1002/1873-3468.12702</ext-link>)<pub-id pub-id-type="pmid">28555747</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C205">
<label>205</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leoncini</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Cytokine dysregulation in MECP2- and CDKL5-related Rett syndrome: relationships with aberrant redox homeostasis, inflammation, and ω-3 PUFAs</article-title>. <source/>Oxid. Med. Cell. Longev.
<volume>2015</volume>, <fpage>421624</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2015/421624">doi:10.1155/2015/421624</ext-link>)<pub-id pub-id-type="pmid">26236424</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C206">
<label>206</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>MacDonald</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Molyneaux</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Azim</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Macklis</surname><given-names>JD</given-names></name></person-group>
<year>2016</year>
<article-title>Reduction of aberrant NF-κB signalling ameliorates Rett syndrome phenotypes in Mecp2-null mice</article-title>. <source/>Nat. Commun.
<volume>7</volume>, <fpage>10520</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncomms10520">doi:10.1038/ncomms10520</ext-link>)<pub-id pub-id-type="pmid">26821816</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C207">
<label>207</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Krishnan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Connors</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Choy</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Page</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Peti</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Van Aelst</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Shea</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Tonks</surname><given-names>NK</given-names></name></person-group>
<year>2015</year>
<article-title>PTP1B inhibition suggests a therapeutic strategy for Rett syndrome</article-title>. <source/>J. Clin. Invest.
<volume>125</volume>, <fpage>3163</fpage>–<lpage>3177</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI80323">doi:10.1172/JCI80323</ext-link>)<pub-id pub-id-type="pmid">26214522</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C208">
<label>208</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janc</surname><given-names>OA</given-names></name>, <name name-style="western"><surname>Hüser</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Dietrich</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kempkes</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Menzfeld</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hülsmann</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Müller</surname><given-names>M</given-names></name></person-group>
<year>2016</year>
<article-title>Systemic radical scavenger treatment of a mouse model of Rett syndrome: merits and limitations of the vitamin E derivative Trolox</article-title>. <source/>Front. Cell. Neurosci.
<volume>10</volume>, <fpage>266</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fncel.2016.00266">doi:10.3389/fncel.2016.00266</ext-link>)<pub-id pub-id-type="pmid">27895554</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C209">
<label>209</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castro</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Garcia</surname><given-names>RI</given-names></name>, <name name-style="western"><surname>Kwok</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Banerjee</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Petravicz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Woodson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mellios</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tropea</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sur</surname><given-names>M</given-names></name></person-group>
<year>2014</year>
<article-title>Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>111</volume>, <fpage>9941</fpage>–<lpage>9946</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1311685111">doi:10.1073/pnas.1311685111</ext-link>)<pub-id pub-id-type="pmid">24958891</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C210">
<label>210</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tropea</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Giacometti</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>NR</given-names></name>, <name name-style="western"><surname>Beard</surname><given-names>C</given-names></name>, <name name-style="western"><surname>McCurry</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Flannery</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jaenisch</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sur</surname><given-names>M</given-names></name></person-group>
<year>2009</year>
<article-title>Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>106</volume>, <fpage>2029</fpage>–<lpage>2034</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0812394106">doi:10.1073/pnas.0812394106</ext-link>)<pub-id pub-id-type="pmid">19208815</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C211">
<label>211</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hara</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Disturbance of cardiac gene expression and cardiomyocyte structure predisposes Mecp2-null mice to arrhythmias</article-title>. <source/>Sci. Rep.
<volume>5</volume>, <fpage>e11204</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/srep11204">doi:10.1038/srep11204</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C212">
<label>212</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crosson</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Evaluation of QTc in Rett syndrome: correlation with age, severity, and genotype</article-title>. <source/>Am. J. Med. Genet.
<volume>173</volume>, <fpage>1495</fpage>–<lpage>1501</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajmg.a.38191">doi:10.1002/ajmg.a.38191</ext-link>)<pub-id pub-id-type="pmid">28394409</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C213">
<label>213</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Connor</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Zayzafoon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Farach-Carson</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Schanen</surname><given-names>NC</given-names></name></person-group>
<year>2009</year>
<article-title>Mecp2 deficiency decreases bone formation and reduces bone volume in a rodent model of Rett syndrome</article-title>. <source/>Bone
<volume>45</volume>, <fpage>346</fpage>–<lpage>356</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bone.2009.04.251">doi:10.1016/j.bone.2009.04.251</ext-link>)<pub-id pub-id-type="pmid">19414073</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C214">
<label>214</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>CS</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>Loss of MeCP2 causes urological dysfunction and contributes to death by kidney failure in mouse models of Rett syndrome</article-title>. <source/>PLoS ONE
<volume>11</volume>, <fpage>e0165550</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0165550">doi:10.1371/journal.pone.0165550</ext-link>)<pub-id pub-id-type="pmid">27828991</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C215">
<label>215</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assadi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Crowe</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rouhi</surname><given-names>O</given-names></name></person-group>
<year>2006</year>
<article-title>Hyperkalemic distal renal tubular acidosis associated with Rett syndrome</article-title>. <source/>Pediatr. Nephrol.
<volume>21</volume>, <fpage>588</fpage>–<lpage>590</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00467-006-0029-2">doi:10.1007/s00467-006-0029-2</ext-link>)<pub-id pub-id-type="pmid">16511686</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C216">
<label>216</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>R-H</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>An X chromosome-wide association study in autism families identifies TBL1X as a novel autism spectrum disorder candidate gene in males</article-title>. <source/>Mol. Autism
<volume>2</volume>, <fpage>18</fpage> (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/2040-2392-2-18">doi:10.1186/2040-2392-2-18</ext-link>)<pub-id pub-id-type="pmid">22050706</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C217">
<label>217</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pons</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cordier</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Labalme</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Till</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Louvrier</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Schluth-Bolard</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lesca</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Edery</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sanlaville</surname><given-names>D</given-names></name></person-group>
<year>2015</year>
<article-title>A new syndrome of intellectual disability with dysmorphism due to TBL1XR1 deletion</article-title>. <source/>Am. J. Med. Genet. Part A
<volume>167</volume>, <fpage>164</fpage>–<lpage>168</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajmg.a.36759">doi:10.1002/ajmg.a.36759</ext-link>)</mixed-citation>
</ref>
<ref id="RSOB170216C218">
<label>218</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinen</surname><given-names>CA</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>A specific mutation in TBL1XR1 causes Pierpont syndrome</article-title>. <source/>J. Med. Genet.
<volume>53</volume>, <fpage>330</fpage>–<lpage>337</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/jmedgenet-2015-103233">doi:10.1136/jmedgenet-2015-103233</ext-link>)<pub-id pub-id-type="pmid">26769062</pub-id></mixed-citation>
</ref>
<ref id="RSOB170216C219">
<label>219</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saitsu</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>A girl with West syndrome and autistic features harboring a de novo TBL1XR1 mutation</article-title>. <source/>J. Hum. Genet.
<volume>59</volume>, <fpage>1</fpage>–<lpage>3</lpage>. (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/jhg.2014.71">doi:10.1038/jhg.2014.71</ext-link>)</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>